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Innovative gastrointestinal (GI) drug delivery vehicles such as mucus penetrating 
nanoparticles (MPP) and fluid-absorption inducing (hypotonic) delivery vehicles have 
potential to improve therapeutic outcomes over conventional methods such as 
mucoadhesive particles (MAP) for GI diseases, including ulcerative colitis (UC) and HIV 
pre-exposure prophylaxis (PrEP). More than 80% of all drugs are absorbed via the GI 
tract for either systemic or local treatment. MAP delivered to the GI tract are thought to 
improve oral absorption or local targeting of difficult-to-deliver drug classes. Mucus is a 
continuously secreted barrier that effectively traps foreign particulates to protect the 
underlying epithelium. Rapid clearance of the most superficial luminal mucus layers in 
the GI tract may limit the effectiveness of MAP. Here, I test the current dogma of 
mucoadhesion by comparing MAP and MPP GI drug delivery via the oral and rectal 
routes. In addition I investigate the development of several vehicles including rectal 
enemas and gels for more effective delivery of nanocarriers or free drugs.  
First, I illustrate that MPP uniformly coat all surfaces of the GI epithelium, while 
MAP aggregated in mucus in the center of the lumen, far away from the absorptive 
epithelium, both in healthy mice and mice with UC. In the mouse colorectum, MPP 
penetrated into mucus in the deeply in-folded surfaces to evenly coat the entire epithelial 
surface. Moreover, in UC mice, MPP were transported preferentially into the disrupted, 
ulcerated tissue. Next, I sought to design an effective enema vehicle for delivering MPP 
and non-mucoadhesive drugs locally to the colorectum. I found that MPP and free drug 
are only rapidly transported to the epithelial surface in sodium-based enemas, while 
potassium-based or isotonic and hypertonic (secretion-inducing) enemas cause 
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heterogeneous surface coverage. Strongly hypertonic and hypotonic enemas cause rapid 
systemic drug absorption, while moderately hypotonic enemas improve local drug 
retention in tissue. Finally, I designed a microbicide-loaded MPP for PrEP, to be 
delivered in a novel osmotic thermogel. The MPP formulation evenly coated both the 
vaginal and colorectal epithelium and the hypotonically delivered thermogel effectively 
traps HIV, and significantly enhances drug and nanoparticle retention in the 
cervicovaginal tract.  
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1. INTRODUCTION AND SIGNIFICANCE 
More than 80% of all drugs are delivered to the gastrointestinal (GI) tract for either 
systemic or local treatment or prevention of diseases 1-3. To achieve optimal drug 
absorption, medications need to reach as much of the epithelial tissue as possible 4-7. 
However, the high tortuosity of the GI epithelium and the sticky mucus barrier coating 
the GI epithelium make this difficult, especially for drugs with poor water solubility 4, 8-
10. Mucus is the first line of defense at mucosal surfaces, effectively trapping most 
pathogens and particulates by hydrophobic and electrostatic interactions 8, 9.  
Hydrophobic drugs will interact with the mucus barrier and can become trapped in it 
11-14. The incorporation of these drugs into nanotechnology has significantly improved 
their solubility and thus their drug absorption; however, most GI nanocarriers have been 
designed to adhere to mucus. Mucoadhesion can limit nanocarrier distribution on the 
epithelial surface and likely leads to their clearance along with the mucus layer 5-7, 15. 
Nanoparticles designed to slip through the mucus barrier may be able to reach the more 
slowly cleared adherent mucus layers and thus may enhance GI drug distribution and 
retention. Optimizing nanoparticle size and surface characteristics that makes them 
mucus penetrating is thus of particular importance. Hydrophilic drug molecules, unlike 
hydrophobic drugs, have little interaction with mucus, are able to diffuse through the 
mucus barrier and take advantage of fluid flow toward the epithelium, or advection 
(directional fluid flow), that leads them to effectively reach the underlying epithelium 11, 
16, 17. Fluid flow toward the epithelium naturally occurs in the small intestine, as outlined 
in Chapter 2, but many vehicles for local delivery to the colorectum are not designed with 
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fluid flow absorption in mind. To optimize colorectal drug delivery of hydrophilic drugs 
or non-mucoadhesive nanoparticles, the design of an optimal delivery vehicle is essential.  
In chapter 2 of this thesis I introduce the mucus barrier, fluid absorption throughout 
the GI tract, the development of mucus penetrating nanoparticles (MPP) for GI 
applications, the treatment of inflammatory bowel disease (IBD) and prevention of 
sexually transmitted infections (STIs) that could benefit from the use of MPP and drug 
delivery vehicles designed with fluid absorption in mind. In Chapter 3, I show the surface 
characteristics and sizes necessary to make nanoparticles MPP in the different parts of the 
GI tract, their distribution on GI tissue, and the effects of fluid absorption on their 
distribution in healthy and inflamed tissue. In Chapter 4, I discuss the effects of ion 
composition of an enema formulation on the distribution of MPP and free drug, local 
toxicity, and drug pharmacokinetics. Chapter 5 outlines the development of a mucus 
penetrating nanocrystal formulation and an osmotic thermogel for improved distribution 
and retention of anti-HIV drugs in the colorectum and cervicovaginal tract. In addition, in 
Appendix I, I address the paradox that only low molecular weight (MW) poly(ethylene 
glycol) (PEG) would result in non-mucoadhesive coatings while the use of high MW 
PEG would cause mucoadhesion, by illustrating that sufficiently dense high MW PEG 
coatings indeed result in particles that are non-mucodhesive. In Appendix II, I discuss the 
use of another class of nanocarriers, dendrimers, for application in the GI tract and other 
mucosal surfaces including the respiratory and cervicovaginal tracts. 
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2. BACKGROUND – CONSIDERATIONS FOR GASTROINTESTINAL DRUG 
DELIVERY  
2.1 Mucus 
Our gastrointestinal (GI) tract has many quite remarkable functions. For example, it uses 
strong acids in the stomach to disinfect and break up peptides, all without breaking down 
its own cell membranes. It is also the home to 90% of our non-eukaryotic inhabitants: 
~1014 bacteria and viruses; however, most of the time we do not get infected 18.  The dead 
and keratinized ‘horny’ cell layers of our skin protects most of our exposed outer 
surfaces, but it is mucus that protects all our moist most mucosal surfaces. Most of us 
usually experience mucus as the slimy, yucky substance we produce when we have a 
stuffy nose or a chest cold, but mucus is the reason enormous moist mucosal surfaces of 
our gut, lungs, mouth, eyes, and reproductive tracts, usually do not get infected. How 
does mucus protect these surfaces? First, it is an excellent lubricant that protects against 
mechanical damage. Second it is remarkable ‘filter’ that traps pollutants, irritants, dust, 
and pathogens and is then rapidly cleared from the body or sent to the stomach to be 
sterilized by acid 8.  
Mucus forms a porous hydrogel that traps pathogens and particulates via size 
exclusion as well as electrostatic and hydrophobic interactions, and also by the selective 
trapping actions of secreted antibodies 9, 19, 20. The gel properties of mucus are produced 
by mucin fibers. Mucins are peptidoglycans 0.3-2 MDa in size 8, 9: they have a long 
peptide backbone that is highly glycosylated. The outermost tips of the sugars (glycans) 
on mucins are negatively charged, giving an overall negative charge to mucin fibers 8, 9. 
This effectively traps many pathogens or particulates that have a positive charge. In 
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addition to the glycosylated regions, the mucin peptides also contain hydrophobic regions 
that bundle mucin fibers into cables, and effectively trap hydrophobic particulates 8, 9. 
Mucin fibers are extraordinarily long, and are linked together to form fibers several 
microns long. Antibodies secreted into mucus greatly enhance the ability to trapping 
pathogens and toxins in mucus gel. Most antibodies synthesized by the immune system 
are secreted into mucus. They diffuse rapidly through the gel, retarded only slightly by 
transient, low affinity bonds with the mucus gel 21. However, when they accumulate on 
the surface of a pathogen they form enough multivalent adhesive interactions with the gel 
to trap the pathogen 22, 23. Once particles, pathogens, or cells are trapped in mucus, they 
are cleared along with it: mucus is constantly secreted and cleared to further prevent 
pathogens and harmful particulates from reaching the surfaces of our mucosal epithelia. 
The types of components, their ratios, the mucin type, the mucus turnover rate, and the 
mucus thickness vary at the different parts of the body and throughout the GI tract, as 
illustrated in Table 2-1. 
The lubricant characteristic of mucin gels arises from their shear-thinning 
viscoelasticity. This lubricating action is of particular importance in the GI tract, where 
undigested, fibrous and often jagged surfaces of chyme are transported by peristalsis 
along the entire 7-8 m of the small and large intestine. Shear thinning occurs when two 
surfaces move by each other and a slippage plane forms midway between the surfaces 9. 
Thus each surface retains and unstirred layer of mucus coats and adheres to the bolus of 
chyme (food) and another layer adheres to the epithelial surface. Despite peristalsis 
occurring all along the intestine, the unstirred mucus layers remain essentially intact and 
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nutrients and particulates must diffuse through these adherent layers to reach the 
absorptive epithelium 8, 9.  
2.1.1 Stomach 
Mucus in the stomach has two layers: the firmly adherent inner layer and the 
loosely adherent outer layer. The inner mucus layer is anchored to the epithelial cells and 
mainly made of MUC5AC, which serves as a barrier to the stomach acid, hydrogen 
chloride (HCl) 24. HCl produced by the parietal cells can penetrate through this layer via 
temporary canals 4, 24-26. The epithelial cells excrete bicarbonate locally that leads to a 
gradient of pH that goes from near-neutral close to the epithelial cells and highly acidic in 
the lumen of the stomach. The outer mucus layer consists mainly of MUC6 and is 
thought to have an additional hydrophobic barrier composed of zwitterionic 
phospholipids that prevents the stomach acid from leaking back to the epithelial layer 
once it is secreted 27-29. Mucus has also recently been found to be resistant to changes in 
pH, making it a formidable protective barrier for the gastric epithelium against the highly 
acidic stomach contents 30. When this barrier is compromised, the epithelial tissue can be 
damaged, making it easier for infections to occur and ulcers to form 4, 31.  
2.1.2 Small Intestine 
The small intestine has a loosely adherent outer mucus layer and is thought to also 
have a very thin inner mucus layer though this has not been confirmed in humans 31. The 
outer layer consists mainly of MUC2 mucin that mainly lubricates the food boluses 
coming through the small intestine for digestions 31. The mucus layer of the small 
intestine is relatively thin compared to the stomach and colon, largely due to the 
difference in function of the small intestine. The small intestine serves mainly to digest 
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and absorb nutrients and is kept quite sterile; after most bacteria and viruses are 
eliminated in the stomach, additional bacteriocidal peptides and proteins that are secreted 
by Paneth cells and enterocytes 32-34. In fact, one could argue that mucus also ought to be 
digested by all the enzymes present in the small intestine, but mucins are actually only 
slowly degraded, suggesting that they must have co-evolved with digestive enzymes to 
resist degradation. Rapid mucus secretion from the crypts also prevents digestive 
enzymes as well as bacteria from reaching the epithelial layer in the small intestine 31, 33. 
Disruption of the mucus barrier can thus lead to infections, epithelial injury by digestive 
enzymes, and chronic inflammatory diseases such as inflammatory bowel disease.  
2.1.3 Colon 
The large intestine, or colon, has a thick inner and outer mucus layer both 
composed of mainly MUC2 mucin produced by goblet cells. In the inner mucus layer, 
MUC2 expands >1000 fold after secretion and forms lamellar sheets that effectively 
prevent bacterial penetration 33, 35, 36. Once these sheets reach the threshold to the outer 
mucus layer, they are further cleaved to allow a 3-4 fold expansion that results in a more 
loosely adherent layer 37. The outer mucus layer allows bacterial penetration and forms 
the home of the most of our gastrointestinal microbiome. The relationship with these 
bacteria is mutually beneficial, as the mucus they live in provides part of their food 
source, while the bacteria produce short chain fatty acids, acetate, and other nutrients for 
our colonic epithelium 38. However, these bacteria commensal can be harmful when they 
reach and infect our epithelial cells. For this reason, the colonic mucus layers are several 
hundred microns thick in humans and are constantly secreted and cleared upon 
defecation. When the mucus barrier is compromised, as it is in certain chronic 
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inflammatory diseases like ulcerative colitis, bacteria are able to reach and infect the 
epithelium. 
2.2 Food absorption and the mucus filter barrier 
To effectively absorb nutrients via the GI tract, nutrients must get through the constantly  
secreted and sloughed mucus barrier. Digestive enzymes make hydrolytic cleavages that 
fragment ingested food into small pieces and molecules in our gastrointestinal lumen and 
must get to the epithelium to be absorbed. With mucus secretion occurring at a velocity 
of about 0.2-2 µm/s, diffusion alone would not be sufficient to bring food particulates and 
molecules close enough to the epithelium for absorption. The body has developed a 
clever way to overcome this barrier: fluid flow. Nine liters of fluid enter our GI tract per 
day, of which >95% is reabsorbed 8, 39. This creates fluid flux from the lumen to the 
epithelium at a velocity of 1-10 µm/s, and this fluid flow can drag along (advectively 
transport) food particulates and small molecules, provided they can penetrate the mucus 
barrier.  This rapid advective transport delivers nutrients to the base of the villi for 
absorption in a matter of minutes. Fluid secretion and re-absorption is brought about by 
ion transport, the details of which are discussed in the next section. In fact, the body uses 
ion transport to drive both water secretion and water absorption, since transporting ions is 
much more efficient than directly transporting molecules of water: Water has a molarity 
of 55M (based on the density, 1000g/L, and molecular weight, 18g/mol, of water), the 
molarity of serum solutes is about 1/3M (~300mM), and therefore for every one solute 
molecule there are ~180 water molecules 40. Each single solute molecule transported will 
thus cause ~180 water molecules to follow by osmosis. Pumping ions is even more 
efficient, since for every actively pumped cation an anion will follow, to maintain electric 
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charge balance, so for every ion that is actively pumped, one counterion and ~360 water 
molecules follow! 
2.3 Fluid flow in the gastrointestinal tract 
2.3.1 Ion movement 
Most nutrient absorption occurs in the small intestine. Enzymes and other digestive 
molecules break up carbohydrates and proteins, and emulsify lipids in the mouth and 
stomach prior to entering the duodenum. In the duodenum, proteases, amylases and 
lipases further break down these nutrients until they are small enough to diffuse to the 
brush-border epithelial cells 41. Then, brush-border hydrolysis breaks the arriving 
molecules into absorbable pieces; e.g. sucrose (table sugar) is broken into fructose and 
glucose and then absorbed by glucose transporters. Many of the nutrient transporter 
proteins require co-transport of ions to allow absorption 42. The ion transport, mainly 
sodium transport, also drives water movement across the epithelial surface, and the water 
in turn drags along nutrients and small molecule drugs toward the cells for brush-border 
hydrolysis and absorption. This continuous cycle is mainly driven by ion gradients 
established by the highly elaborate ion channel and transport systems of the small 
intestinal enterocytes.  
The large intestine also takes advantage of ion-transport driven water absorption: 
its main job is to re-absorb fluid from and nutrients produced by bacteria that are further 
digesting the chyme exiting the small intestine. The colorectum is inhabited by a vast 
number and types of bacteria that break down indigestible food molecules to use as fuel 
for themselves and produce short chain fatty acids such as propionate, acetate, and 
butyrate, of which butyrate in particular serves as nutrient for colonocytes 31. These 
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nutrients must penetrate the thick colonic mucus layer to reach the epithelium, but would 
fail to do so if the osmotic gradient resulting from digestive processes were not counter-
acted by an osmotic gradient created by active ion absorption 42. The body again employs 
an elaborate ion channel and transport system in the large intestinal enterocytes to 
maintain a continuous ion, and hence water absorption by the colorectal epithelium.  
2.3.1.1 Small intestine 
When acidic chyme is transported by peristalsis from the stomach to the small intestine, 
bicarbonate is secreted primarily by the pancreas neutralize it, but also by local secretion 
in the duodenum 31, 39, 42. This occurs via chloride-bicarbonate exchangers or anion 
selective channels in the apical membrane. When a meal is consumed, the expression of 
ion-dependent and ion-independent solute carriers is upregulated. In fact many important 
nutrients such as glucose, fructose, and galactose are transported via sodium-dependent 
transporters, leading to a net uptake of sodium 39, 42. To ensure sodium will travel down a 
concentration gradient, the newly absorbed sodium ions travel across the cell and are 
shuttled out via basolateral sodium-potassium pump into the interstitial spaces 42. Anions 
like chloride follow passively creating electroneutral transport. In the starved state, ion 
absorption does not stop and now occurs via solute-independent exchangers. In the 
proximal bowel, chloride ion transport is passive and simply follows sodium transport to 
make total ion transport electroneutral. If luminal chloride levels need to be increased, 
cells located closer to the base of the villi will secrete chloride by absorbing from the 
basolateral side 39, 42. A sodium-potassium pump then transports sodium back out of the 
cell and potassium exits the at the basolateral side via potassium channels. Chloride will 
exit the cell via chloride channels.  
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2.3.1.2 Large Intestine 
In the colon, just like the small intestine, the primary ions shuttled for fluid absorption are 
sodium, bicarbonate, chloride, and hydrogen. Ion movement into cells in the large 
intestine mainly occurs via ion exchangers in the apical membrane that pump sodium and 
chloride into the cells while bicarbonate and hydrogen are secreted 42. Sodium and 
chloride transport are not necessarily dependent on each other; for example, the apical 
membranes of the colonic epithelium also contain epithelial sodium channels that allow 
sodium diffusion into the cell along its osmotic gradient 39, 42. Low intracellular sodium 
concentrations are maintained via sodium-potassium pumps in the basolateral membrane. 
In the colon, unlike in the small intestine, potassium is then secreted via potassium 
channels in the apical membrane 42. Potassium secretion and sodium absorption are both 
stimulated by chyme reaching the large intestine.  
2.3.2 Water movement 
The constant sodium flux across the epithelial cells causes water movement across the 
epithelial layer as well. Based on osmotic pressure differences, every single sodium ion 
that crosses the epithelial membrane will cause ~360 water molecules to follow (as 
explained earlier). It has long been thought that water transport mainly occurs via 
paracellular routes, or through the tight junctions, as water will simply follow the ions. 
Indeed, the lower electrical resistance of cells in the small intestine 43-45 seems to indicate 
that they are “leaky” and allow rapid water movement. This is also supported by the low 
osmotic permeability of membrane vesicles derived from small intestinal cells 46, 47. 
However, it has recently been shown that water transport via the paracellular route is 
limited and cannot account for all water absorption occurring in the small intestine 48-52. 
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Further research has indicated that aquaporins shuttle water across the cell membrane in 
an osmosis-driven process 53. In addition, ion and solute channels can also carry a 
significant number of water molecules along with the solute 48, 54, 55. The low 
permeability of the colonic epithelium makes it highly likely that transcellular movement 
via aquaporins and ion channels is actually the main route of water movement in the 
colorectum 48, 54. 
2.3.2.1 Role of aquaporins in water movement 
Aquaporins have received more attention as vehicles for water movement in recent years. 
In the small intestine aquaporin expression suggests that aquaporins help mediate water 
absorption rather than secretion 48. In both the large and small intestine, aquaporins have 
been identified in the basolateral and apical enterocyte membranes indicating that water 
can indeed travel through the epithelial cells via aquaporin channels 48. This occurs via an 
osmosis-based process, where aquaporins allow water movement from less to more 
concentrated solutions. However, as food is digested, the process of cleaving proteins, 
carbohydrates, and other nutrients into smaller and smaller fragments, increases 
osmolality in the GI lumen to be > 200 mOsm higher than in the blood. If water was only 
moving passively down its concentration gradient, this would result in water being drawn 
rapidly into the lumen. It is known, though, that the GI tract absorbs water very 
effectively despite the opposing osmotic gradient, and that active ion transport causes the 
net absorption of water in both the small and large intestines 54. It is thus newly stipulated 
that water is not only absorbed via osmotically driven aquaporin channels, but is also 
transported in solute transporters.   
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2.3.2.2 Role of solute transporters in water movement 
Researchers over the past twenty years have found more and more indications that 
aquaporins are not the only water-transporting proteins. In fact many solute and ion 
transporters also cotransport water; this has been illustrated for a variety of transporters 
present in the GI tract 54. Each transporter carries a specific number of water molecules in 
each turnover cycle ranging from 40 water molecules per glucose molecule in GLUT2 56 
to 590 water molecules per Na+/K+/2Cl- ions in NKCC1 57. These transporters are able 
to actively pump ions and solutes, and thus water, opposing osmotic gradients like those 
established in the GI tract during digestion. In addition, the number of water molecules 
transported is not altered when surrounding electrical gradients, concentration or osmotic 
gradients are changed – the ratio is strictly stoichiometric 54.   
2.3.3 Implications for drug delivery  
Nutrients are not the only solutes associated with transport across the GI epithelium: 
medications that mimic nutrients also often take advantage of solute transporters that will 
co-transport them along with water from the lumen into the cells. Similar to food 
particulates and molecules requiring a driving force, i.e. water flow, to get past the 
constantly secreted mucus barrier, drug molecules also take advantage of fluid flowing 
toward the epithelium 11, 16, 58. Hydrophilic small molecules in particular, such as drugs 
mimicking amino acids or nucleotides, can rapidly diffuse through mucus barrier and are 
rapidly dragged toward the epithelium by the water flux 11, 16, 17. However, mucus, as 
described in Section 2.1, consists of mucins with highly negatively charged glycosylated 
regions. Positively charged drug molecules and polyvalent ions can transiently or 
permanently bind to these negatively charged glycans, leading to slower diffusion or 
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entrapment in mucus 8, 11, 16. Similarly, lipophilic drug molecules are known to bind to 
non-specifically to proteins like mucins 11, 16. Indeed, the affinity between lipophilic 
drugs and mucus has been studied extensively. Researchers have shown that the 
absorption rate of lipophilic progesterone is dependent on the mucus layer, while less 
lipophilic hydrocortisone absorption is controlled by the epithelial membrane 59. In 
addition, testosterone along with several other lipophilic drug molecules were found to 
bind to and diffuse more slowly through pig intestinal mucus than hydrophilic molecules 
12-14. Although the movement of these individual molecules is significantly slowed in 
mucus, the transience of their interactions with mucus allow for their absorption, which is 
further improved by water absorption driving the individual molecules to the epithelium 
9.  
 While water can drag individual lipophilic drug molecules through mucus and to 
the epithelium, these drugs do not readily dissolve in the gastrointestinal secretions 11. 
Therefore only a small, dissolved fraction will actually reach the epithelium, while the 
rest of the molecules are suspended in bile salt-coated lipid droplets. These droplets, or 
micelles, range from 23-35 nm, making them large enough so that diffusion to the 
epithelial surface would take not suffice to bring them to the absorptive epithelium 58, 60. 
Recent advances have shown that bile salts prevent particulates from adhering to mucus 
60 and we have shown in this work and previously in the cervicovaginal tract that only 
non-mucoadhesive particulates can take advantage of fluid flow to get to the epithelial 
surface 61. Intestinal mixed micelles, which are coated with bile salts, can thus be dragged 




 Protein-based therapies are a newer class of drugs. Because peptides denature and 
are broken down easily, they need to be protected against the low pH of stomach acid and 
the digestive enzymes in the stomach and small intestine. Researchers have found that 
bioavailability of peptide drugs is significantly enhanced by their encapsulation into 
nanocarriers 3, 62, 63. Similar to the bile-salt coated micelles, nanocarriers also need to be 
able to traverse the mucus barrier to reach the underlying epithelium for absorption. Most 
nanocarriers exceed the size of bile-salt coated lipids and thus pure diffusion does not 
suffice for them to reach the GI epithelium. Here water absorption again aids in dragging 
nanocarriers through mucus and to the epithelium; however, many nanocarriers are 
composed of hydrophobic polymers that would likely stick to the mucus barrier. Our 
laboratory has previously developed stealth-nanoparticles that are able to penetrate 
through human and mouse mucus at a variety of mucosal surfaces 7, 15, 64-68. The next 
section discusses what properties can make nanoparticles non-mucoadhesive, how these 
nanoparticles can be used as biophysical tool to characterize mucus, and how they can be 
used to determine whether or not fluid absorption is occurring.  
2.4 The mucus barrier, fluid absorption, and drug delivery using nanoparticles 
Nanocarriers delivered to the GI tract can be effectively trapped in mucus by size 
exclusion or hydrophobic and electrostatic interactions. GI drug delivery research has 
mainly focused on developing nanoparticles that strongly adhere to mucus, assuming that 
this will increase nanoparticle residence time, which would lead to improved drug 
absorption 69. However, since these nanoparticles stick to the rapidly cleared sloppy 
mucus layer, they will likely also be rapidly cleared 4, 5, 7, 70. To overcome the mucus 
barrier, our group, inspired by the mucoinert nature of some viruses, has developed 
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nanoparticles that rapidly diffuse through mucus. We have shown that these mucus 
penetrating nanoparticles (MPP) can penetrate through the loosely adherent and into 
more slowly cleared mucus layers, leading to improved drug and gene delivery at 
mucosal surfaces 5, 7. In addition, Ying-Ying Wang in 5 has shown that mucoadhesive 
nanoparticles are unable to take advantage of fluid flow. I have already described how 
fluid flow in the GI tract can aid in the absorption of nutrients by transporting them 
through mucus and to the epithelial surface. Mucoadhesive particles are unable to be 
dragged along with water flow in the GI tract; MPP, however, are able to utilize both 
inherent and induced fluid absorption to further improve their distribution and retention.  
2.4.1 Surface characteristics that yield MPP  
We have recently demonstrated that nanoparticles densely coated with polyethylene 
glycol (PEG) are able to effectively diffuse through human mucus. Previous research 
indicated that PEG polymers are able to interact with mucins by hydrogen bonding and 
interpenetration into the mucus network, leading to mucoadhesion 71-74. Our group further 
investigated the effects of PEG coatings on nanoparticle interaction with mucus. We 
demonstrated that nanoparticles coated densely enough with low molecular weight 
(MW), <10 kDa, PEG could indeed avoid interaction with the mucus barrier 15, 75. When 
more than 60% of the surface of hydrophobic, mucoadhesive nanoparticles (MAP) was 
coated with 2 kDa PEG, their transport rates increased >700-fold compared to those with 
approximately 40% less PEG on their surface 75. The particles coated with low-density 
PEG had transport properties equivalent to uncoated nanoparticles.  
PEG coverage of nanoparticles can also be correlated to their surface charge, 
namely their ζ-potential. Based on the existing literature and our work, we determined 
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that a near-neutral ζ-potential is necessary to indicate that a nanoparticle is mucus 
penetrating. The threshold for this lies between -7 mV and -10 mV and nanoparticles 
with a ζ-potential ≤ -10mV will be mucoadhesive 75. In the same studies we found that 
coating nanoparticles with 10 kDa PEG at a similar density as 2 kDa PEG (67% for 2 
kDa PEG vs 64% for 10 kDa PEG) caused them to be mucoadhesive 75. We postulated 
that this was due to the previously mentioned interpenetration and hydrogen bonding of 
PEG molecules with the mucus mesh. New data presented in Appendix I indicates that 
MPP can be obtained by coating nanoparticles with PEG MW ≤ 40 kDa.  
2.4.2 MPP for mucosal drug delivery 
Nanoparticles provide significant advantages for drug delivery compared to free drug 
vehicles by providing sustained release, surfaces for attaching targeting moieties, and 
protection against stomach acid and digestive enzymes. Biodegradable nanoparticles are 
preferred for drug delivery. Our group has thus focused on creating drug-loaded, 
biodegradable MPP formulations. We have accomplished this both by chemically 
conjugating PEG to hydrophobic polymers, such as poly(lactic-co-glycolic acid) (PLGA), 
to ensure sufficient PEG coating on the surface as well as by using all Generally 
Regarded as Safe, or GRAS, materials such as PLGA coated with Pluronic ® 76, 77. We 
determined that not all Pluronic ®  types sufficiently coat nanoparticles with PEG: 
Pluronics ® are triblock copolymers that contain two PEG chains attached to a 
poly(propylene oxide) (PPO) and only pluronics ® with a PPO chain > 3 kDa and PEG 
chain of 2 kDa or 5 kDa in size actually make nanoparticles penetrate mucus 77. 
Nanoparticles made with polymers containing covalently bound PEG often require the 
addition of the original polymer to obtain sufficient drug loading (unpublished data and 6, 
17 
 
78). However, if nanoparticles are made with insufficient PEG-polymer, this will lead to 
insufficient PEG coverage, similar to what we illustrated with non-biodegradable MPP 6, 
75, 78. We also recently showed that nanoparticles made via the emulsion method require 
the addition of low molecular weight surfactants to make MPP. When high molecular 
weight surfactants were used, nanoparticles were immobilized in mucus, likely due to 
disruption of the integrity of the PEG architecture on the particle surface 78.  
 For a long time, mucosal drug delivery focused on making nanoparticles 
mucoadhesive in order to improve their retention time. We hypothesized that MPP, due 
to their ability to diffuse in mucus, would be able to penetrate into more slowly cleared 
mucus layers thus improving their distribution and retention over MAP that will stick to 
mucus as soon as they encounter it. Indeed, we have demonstrated that MPP significantly 
improve nanoparticle distribution and retention in the cervicovaginal and respiratory 
tracts over MAP 5-7, 15, 79. In the cervicovaginal tract, we found that MPP can reach all 
portions of the highly folded vaginal epithelial surface and provide >80% tissue coverage 
after 24h, while free drug loaded gels coat <45% of the epithelial surface 5. In addition, 
more than 60% of MPP but only 10% MAP are retained vaginally after a 6 h period 5. In 
addition, drug- loaded MPP provided better protection than a 10-fold higher dose of free 
drug against herpes simplex virus (HSV) when administered 30 min prior to viral 
challenge 5.  
In the respiratory tract, we found that MPP evenly coat the tracheal and bronchial 
epithelium, and smaller MPP were found in close proximity to the epithelial cells 6. In 
contrast, MAP aggregated in clumps away from the epithelial surface. MPP were also 
retained to a much greater degree: after only 2 h, <45% of MAP but >85% of MPP 
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remained in the lungs 6. Similarly, only 25% of biodegradable MAP but >85% 
biodegradable MPP were retained in the lungs after 2 h, a pattern that continued up to 6 h 
post administration 6. In addition to improving retention and distribution, MPP seem to 
induce little to no toxicity, while MAP seem to cause immune cell infiltration in both the 
lungs and CV tract 5, 6. The differences between MPP and MAP have not been elucidated 
for GI drug delivery and thus are explored in Chapter [insert chapter number for MPP vs 
MAP] of this thesis.  
2.4.3 MPP as tool to understand mucosal physiology 
Research has shown that nanoparticles are a useful tool to analyzing biological 
substances, like mucus. In particular, mucus-penetrating nanoparticles have been utilized 
to determine the rheological properties of mucus. These properties are the viscosity, 
represented by the loss (or viscous) modulus G”, and elasticity, represented by the 
storage (or elastic) modulus G’. Bulk rheology of mucus describes it as a viscoelastic 
material, indicating that it can both flow and deform. Mucus is also described as shear-
thinning, such that when high shear rates are applied to it, the resistance to deformation is 
very low, and mucus behaves like a lower viscosity fluid 8. Low shear rates cause high 
resistance to deformation, and mucus behaves more like a solid. While these properties 
very accurately describe the behavior of mucus at the macro scale, it does not provide 
sufficient conclusions about the viscosity and elasticity experienced by a small 
nanocarrier. Indeed, we have shown that nanoparticles that stick to mucus or are larger 
than the mesh spacing experience mucus as having higher viscosity 15, 30, 80. This is 
largely due to the microrheological properties of mucus.  
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 The microrheology of mucus can be studied by following the mean squared 
displacements (MSD) of nanoparticles in mucus. The Laplace transform of MSD can be 
related to the viscoelastic modulus by G (s) = 
𝑘𝑏𝑇
𝜋∙𝑎∙𝑠∙𝑀𝑆𝐷(𝑠)
 where s is the Laplace 
frequency, and when G(s) is projected into Fourier space, this results in the complex 
modulus G*(ω), where the real part is the elastic modulus, G’, and the imaginary part is 
the viscous modulus, G” 80, 81. Viscoelastic materials like mucus can then be categorized 
into viscoelastic solids when G’>G” or viscoelastic liquids when G”>G’. The relationship 
between G” and G’ can also be described using the phase angle, or δ=tan(
𝐺"
𝐺′
) such that a 
viscoelastic solid has δ<45° and a viscoelastic liquid has δ>45° 82, 83. Depending on the 
nanoparticle size and interaction with mucus, it can experience mucus as a viscoelastic 
liquid or viscoelastic solid. For example, MPP<500nm in size experienced mucus as a 
viscoelastic liquid, with δ>60°, while MPP 1 µm in size experienced mucus as a 
viscoelastic solid with δ≈30° 83. Similarly, we found that mucoadhesive nanoparticles 200 
nm in size experienced mucus as a viscoelastic solid, with a microviscosity 7-15 fold 
lower than the bulk viscosity, due to their mucoadhesive interaction with mucus 80. 
Mucoadhesive nanoparticles thus are not effective tools for determining microrheology, 
as the rheology will likely mainly illustrate the contributions from adhesive interactions 
instead of local G” and G’. In stark contrast, we have found that microviscosity 
experienced by 200 nm MPP is 300-1500 times lower than bulk viscosity, and thus MPP 
experience mucus as a viscoelastic liquid and can serve as tool to determine the 
viscoelastic properties of the interstitial spaces in mucus 80, 83. 
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2.4.4 MPP and fluid absorption 
More recently we have also utilized MPP to determine the capability of a drug delivery 
formulation to induce fluid absorption 61. While the distribution of MAP on the vaginal 
epithelium is unaffected by fluid flow from the lumen to the epithelium, MPP distribution 
is significantly different when they are administered in absorption-inducing fluids 
compared to non-absorption-inducing fluids. Fluid flow, or advection, caused by an 
absorption inducing (or hypotonic) vehicle rapidly transports MPP through the mucus 
layer to the epithelial surface, leading nanoparticles to penetrate into the folds of the 
vagina, or rugae, and uniformly coat the entire vaginal epithelium 5, 61. In contrast, MPP 
administered in a vehicle that does not induce advection (or an isotonic vehicle) remain in 
the lumen. We found that fluids that are moderately hypo-osmolar to blood can still cause 
fluid absorption to occur within 5 minutes of administration 61. It is unfortunately difficult 
to use this rapid nanoparticle movement to estimate the actual time needed for and 
amount of fluid absorption occurring. Thus MPP can only serve as tool to determine if a 
vehicle causes fluid absorption or not. In this thesis, I have taken advantage of MPP as 
such a tool in Chapter (insert enema chapter number) to design a hypotonic enema 
formulation for rectal drug delivery with particular focus on the delivery of antiretroviral 
drugs for HIV prevention.  
2.5 Gastrointestinal diseases 
The GI tract, along with our skin, is one of the surfaces on the body with the most contact 
to the external elements. While stomach acid removes many pathogens, the GI tract still 
faces thousands of potential infectious agents – including many viruses and bacteria – on 
a daily basis. If we consider that uncontrolled growth of our commensal bacteria can also 
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turn into disease states, the GI tract is a prime target for infection. Local infections by 
bacteria such as salmonella and viruses such as those causing viral gastroenteritis, can 
lead to many symptoms including diarrhea, vomiting, and nausea. However, our immune 
system or currently available medications can often battle these infections. Chronic 
diseases face unique challenges in that they require long-term drug treatments and often 
causes are not known. One such diseases is inflammatory bowel disease (IBD), where 
patients can experience sever pain, diarrhea, and have ulcers located either to the colon 
(in ulcerative colitis, or UC) or throughout the entire intestine (in Crohn’s disease, or CD) 
84, 85. Other chronic conditions include GI cancers and inflammatory bowel syndrome. In 
addition to chronic diseases of the local epithelium, the GI tract, the colorectum and oral 
cavity in particular, is a major target for infectious agents that can lead to chronic 
systemic illness, such as HIV. Here we summarize current treatment methods for IBD 
and prevention methods for HIV in the GI tract.  
2.5.1 IBD 
Inflammatory bowel disease is quite common in developed nations, affecting about 1.4 
million patients in the US and 2.2 million in Europe 86, 87. Patients experience symptoms 
ranging from GI discomforts such as bloody diarrhea, abdominal pain, and vomiting to 
systemic effects such as weight loss and fever. The disease is believed to be caused by 
both environmental and genetic factors, as factors like the use of oral contraceptives and 
smoking can affect the condition 86, 88-92. IBD presents either as ulcerative colitis (UC), 
which mainly affects the transverse colon, descending colon, and rectum, or Crohn’s 
disease (CD), which can affect the entire GI tract 85, 93. Unfortunately, the exact cause of 
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IBD is still unknown and thus a cure has not been developed; instead, patients receive 
life-long treatment to alleviate symptoms and improve their quality of life.  
Medication for IBD is usually administered via the oral or rectal routes. The rectal 
route has been shown to have significant benefits for UC treatment because it avoids 
first-pass metabolism and high local concentrations of active drugs 94. Rectal 
formulations include enemas, foams, and suppositories containing a variety of anti-
inflammatory drugs such as 5-aminosalicylates (5-ASA) or corticosteroids 95-97. Out of 
these, foams and enemas are most promising, as these can deliver drug throughout the 
entire rectum, sigmoid, and descending colon, unlike suppositories that mainly release 
drug in the rectum itself 98. Colon targeting strategies have also been employed in oral 
delivery of 5-ASA for UC treatments. Many of these release drug on a pH basis, with 
release occurring between pH 4.5 – 7 99, since local inflammation can lead to lower pH 
values than those found in the healthy regions of the GI tract. Several of these have 
demonstrated significant therapeutic success, though differences between individual 
formulations have yet to be demonstrated in large-scale studies 100, 101. 
Another common method to target drugs to the colorectum and improve 
bioavailability is the use of prodrugs. Prodrugs are pharmacologically inactive 
compounds that are converted to their active form by enzymes specifically found in the 
colorectum such as azoreductase, glycosidase, galactosidase, and others 102-106. Some 5-
ASA prodrugs have been found to have significant improvements over the original 5-
ASA compound: patients treated with balsalazide, a sulfa prodrug containing a diazo 
linkage between 5-ASA and 4-aminobenzoyl-β-alanine, had shorter remission times 
(64% vs 43% after only 2 weeks and up to 88% vs 57% after 12 weeks) and more 
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asymptomatic days (10 vs 25 days) compared to the active compound, 5-ASA 107(ref). In 
addition, 60-80% of patients with mild to moderate UC that were treated with osalazine, a 
sulfa prodrug of two 5-ASA molecules, had fewer clinical symptoms and signs 108. The 
use of prodrugs can thus significantly improve outcomes in UC and make safer, more 
efficacious, and more tolerable treatment options. 
Nanotechnology has more recently received significant attention for use in IBD. 
Nanoparticles provide sustained release and offer an easy platform for developing 
targeting strategies that may be implemented to target inflamed tissues 95, 98. Polymeric 
nanoparticles are most commonly made of poly(lactic-co-glycolic acid), a FDA approved 
biodegradable polymer. Investigations using PLGA nanoparticles in murine models of 
IBD have shown that nanoparticle deposition is size dependent, with amount of 
deposition increasing as size decreases: 10 µm < 1000 nm < 100 nm 109. Similarly, 
nanoparticles seemed to preferentially adhere to inflamed tissues, as was shown by both 
oral and rectal administration of drug-loaded nanoparticles that led to 3-fold higher drug 
penetration into ulcerated regions 109-112. Most conventional nanoparticle systems, 
however, firmly adhere to the mucus layer coating the gastrointestinal tract (as described 
earlier) and it is unclear whether or not mucoadhesive or non-mucoadhesive nanocarriers 
would be most beneficial for IBD treatments. Chapter [MPP vs MAP] of this thesis 
discusses the differences in distribution of mucoadhesive and non-mucoadhesive 
nanocarriers in the healthy GI tract. In addition, physiological changes in UC, including 
mucus hypersecretion and increased epithelial permeability, may alter the characteristics 
that are necessary to make MPP for UC 113-116. Recent reports have shown that the mucus 
barrier, in particular the normally impenetrable adherent layer, is broken down and allows 
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both bacteria and PEG-coated nanoparticles as large as 2 µm to penetrate into affected 
regions 109-111, 115. Chapter [insert MPP vs MAP chapter number] also addresses whether 
or not these changes in the mucus barrier can alter whether mucoadhesive or non-
mucoadhesive nanoparticles are preferable for IBD treatments.  
2.5.2 Microbicides for HIV Prevention 
Infection with human immunodeficiency virus (HIV) has long been identified as an 
epidemic and affects more than 35 million people worldwide 117. Eradication of this virus 
once an individual is infected has proven extremely difficult. Many recent efforts have 
therefore focused on developing pre-exposure prophylaxis (PrEP) methods to prevent the 
~2 million new HIV infections occurring every year 117. A significant portion of these 
infections occur due to unprotected receptive anal intercourse (RAI), which can be in part 
led back to the 20-fold increased risk of rectal compared to vaginal HIV transmission 118. 
In addition, while HIV incidence rates have fallen in many populations, the rate of new 
infections seems to be stable or increasing for men who have sex with men (MSM) 119, 
120. There is thus a significant need for the development of rectal microbicides.  
 Rectal microbicides currently in development include oral and rectal 
formulations. The US Food and Drug Association (FDA) has recently approved Truvada 
®, an oral tablet of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), both 
reverse transcriptase inhibitors, as PrEP for high risk populations in the USA  121. Phase 
III clinical trials have shown that a daily oral dose of Truvada ® decreases HIV incidence 
by 44% 122. When evaluating participants with detectable drug-levels, compared to those 
of undetectable levels, the chance of HIV transmission was further decreased to a relative 
92% reduction of transmission 122.  However, researchers have voiced concerns with oral 
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PrEP: systemic exposure may lead to antiretroviral resistance and increased availability 
of oral PrEP may lead to decreased rates of condom use 123, 124. These concerns are less 
evident when considering rectal microbicide delivery.  
Currently, rectal gels are considered the most promising method for rectal PrEP. 
Gels or lubricants are widely used for RAI with separate studies showing use by >89% of 
participants 125, 126. Several gels have been developed as PrEP. One of these is a gel 
containing UC781, a non-nucleoside reverse transcriptase inhibitor, which was studied in 
RMP-01 126. In this Phase I trial gels containing 0.1% or 0.25% UC781 were assessed for 
safety and acceptability. The gels showed mild adverse events (AE) but no changes in 
mucosal safety markers were observed. Tissue biopsies from participants receiving 
0.25% UC781 gel showed marked reduction in tissue of HIV p-24 ex vivo and plasma 
drug levels were undetectable 126, 127. While these results were promising for advancing 
this gel to Phase II development, the US FDA sponsor discontinued clinical development 
of UC781 as a microbicides in 2010 121. 
Perhaps the most commonly studied microbicide gel is a 1% tenofovir (TFV) gel 
formulation. Originally intended as a dual-compartment gel, this formulation was tested 
in the RMP-02/MTN-006 study that showed that rectal gels led to 112-fold higher tissue 
Cmax of tenofovir-diphosphate (the active intracellular product of TFV) than oral 
formulations 30 min after exposure 127. The study reported no serious AE; however, 
repeated dosing of TFV gel was associated with increased AE, in particular GI AE. The 
original formulation was thus deemed unsafe for rectal use, and was later found to be 
associated with epithelial fracture and sloughing 128. The epithelial damage was attributed 
to its high osmolality due to the 20% glycerol content; the drug was then a reformulation 
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into a reduced-glycerol (5%) rectal formulation (RG 1% TFV gel). The RG formulation 
has been investigated for safety in the MTN-007 trial. In this study, three different gels, 
HEC placebo, RG 1% TFV, or 2% nonoxynol 9 (N9, a known spermicide that causes 
epithelial irritation 129), were administered daily for 7 days and safety was assessed via 
histology, fecal calprotectin, epithelial sloughing, cytokine expression (mRNA and 
protein), microarrays, flow cytometry of mucosal T cell phenotype, and rectal microflora 
130. Fecal calprotectin, rectal microflora, and epithelial sloughing showed no difference 
between treatment arms, while histology, mucosal gene expression, protein expression, 
and T cell phenotype showed differences as compared to N9 gel. Overall the RG 1% TFV 
gel was considered both acceptable and safe and has been advanced to Phase II clinical 
trials in the MTN-017 study 121. In addition to MTN-017, a combination rectal 
microbicide gel is under investigation in the Combination HIV Antiretroviral Rectal 
Microbicide (CHARM) Program. This program is currently investigating the safety, 
acceptability, distribution, and pharmacokinetic (PK)/pharmacodynamic (PD) profiles of 
three 1% TFV gels (the original vaginal formulation, the RG formulation, and a rectal 
specific formulation) in two Phase I trials, Charm-01 and Charm-02 121. A third trial, 
Charm-03, aims to compare the safety, acceptability, and PK/PD of oral and rectal gel 
formulations of maraviroc, a CCR5 receptor antagonist.  
Another more recently explored avenue for rectal microbicide is the development 
of a microbicide containing rectal douche (or enema). Many MSM currently used enemas 
prior to RAI, making this another PrEP method that requires little behavioral changes 131. 
Most enemas are used within 0.5-8 h prior to receptive rectal intercourse, such that for a 
microbicide loaded enema no daily administration would be necessary. In addition to 
27 
 
providing little need for behavioral changes, enema formulations have been shown to 
reach significantly larger fractions of the colorectal surface compared to rectal gels 132-134. 
In fact, Leyva et al demonstrated that an iso-osmolar enema led to fluid distributing into 
the descending colon, in some participants all the way to the splenic flexure, after only 2 
h. In contrast, microbicide loaded gels required 24 h to reach the splenic flexure, a time 
that is much too long for a microbicide-loaded lubricant used during intercourse 133. 
Leyva et al also showed that the osmolarity of the enema formulation played a critical 
role in its distribution; hypo-osmolar (tap water) and hyper-osmolar (Fleet ®) enemas 
remained localized to the recto-sigmoid colon 2 h after administration in stark contrast to 
the iso-osmolar enema. The basis of designing enema formulations optimal for  STI 
prevention and the tunability of enema formulations for other diseases is topic of Chapter 
4 of this thesis, and this work in combination with studies by Hendrix et al on use of 
enemas as rectal microbicides has recently been translated into clinical trials via the 
Development of Rectal Enemas as Microbicide (DREAM) Project.  
A novel development in PrEP is the use of nanotechnology to provide sustained 
release and improve solubility of poorly water soluble drugs. Das Neves et al developed a 
dapivirine, a nucleoside reverse transcriptase inhibitor, loaded polymeric nanoparticles 
that, when coated with poly(ethylene glycol) (PEG), provided improved tissue 
penetration and no detectable epithelial toxicity 135-138. Another nanocarrier explored as 
microbicide is the Starpharma’s Vivagel ®, a gel containing the polylysine dendrimer 
known as SPL7013. Dezzutti et al found that a 5% SPL7013 gel was safe on Caco-2 cells 
and reduced HIV infection by over 85% 139; however, this formulation also caused 
epithelial sloughing 140. A 3% SPL7013 gel tested in pigtail macaques was found to be 
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safe after daily administration for three days 141. Nanocarriers used as rectal microbicides 
will face a particular challenge: the mucus barrier, as already discussed in section 2.1. 
The development of a dapivirine nanoparticle that can traverse the mucus barrier is 




Table 2-1. Properties of mucus at various surfaces including thickness, primary mucin 
type, and turnover rate. 







MUC5B 142, 143 
3 – 7 h 144 
Respiratory tract 
Airway 7 – 30 145-147 MUC5AC 
MUC5B 148 
10 – 20 
min 149 Bronchi 50 – 60 150 
Eye 
Mucus 0.02 – 0.05 151 MUC5AC 
MUC1 
MUC4 152 
5 – 8 min 




Stomach 50 – 450 9 MUC5AC MUC6 31 




10 – 40 157, 158 MUC2 31 
Large 
intestine 






3.  EFFECT OF SURFACE CHEMISTRY ON NANOPARTICLE 
INTERACTION WITH GASTORINTESTINAL MUCUS AND 
DISTRIBUTION IN THE GASTROINTESTINAL TRACT FOLLOWING 
ORAL AND RECTAL ADMINISTRATION IN THE MOUSE*
                                                 
* Reprinted from Journal of Controlled Release, Maisel, K. Ensign, L. Reddy, M. Cone, R. Hanes, J. Effect 
of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the 
gastrointestinal tract following oral and rectal administration in the mouse, In press, Copyright 2014, with 





More than 80% of drugs are taken orally, making the gastrointestinal (GI) tract 
the primary site of drug delivery 1-3. Many potent small molecule drugs are hydrophobic 
and poorly water soluble, which often translates into poor oral bioavailability 3. 
Micronization of hydrophobic drugs to increase surface area is a common method to 
improve drug dissolution, thereby enhancing uptake of poorly soluble drugs 3, 162-164. 
Encapsulation within polymer nano- and microparticles is another approach that has been 
demonstrated to improve oral delivery of many types of drugs, ranging from small 
molecules to large proteins 1, 3, 165. However, whether a poorly soluble drug is micronized 
into a suspension of hydrophobic particulates, or any drug is encapsulated within 
conventional polymeric nanoparticles, the final product is typically a hydrophobic 
particle that is strongly adhesive to mucus 4.   
Current dogma suggests that mucoadhesion of particulates is beneficial for 
maximizing delivery in the GI tract. Mucoadhesion purportedly allows the particulates to 
leave the chyme by adhering to the mucus layers lining the GI tract 4, 166, 167. It is widely 
agreed that enhanced drug delivery from the chyme to the entire (highly-folded) GI tract 
epithelium, including the highly absorptive jejunum, where fluid absorption greatly 
speeds nutrient uptake, is desired for maximum absorption into the systemic circulation 4, 
168-171. Furthermore, for treating diseases of the colorectum, such as ulcerative colitis 
(UC), and for preventing rectal transmission of sexually transmitted infections (STI), 
rectal, rather than oral administration, may be more effective 131, 133, 172, 173.        
However, GI tract mucus is a continuously secreted barrier that traps and coats 




recently suggested that it is possible that the rapid clearance of the most superficial 
luminal mucus layers in the GI tract may limit the effectiveness of mucoadhesive 
particles 4. Mucoadhesive nano- and microparticulate formulations have been shown to 
significantly improve delivery of several drug molecules in the GI tract compared to 
drugs administered without a delivery system, at least partly by increasing drug 
solubility, providing sustained release, and protecting the drug cargo. However, it has yet 
to be carefully tested whether mucoadhesive nano- and microparticles provide advantages 
over non-mucoadhesive particles in terms of partitioning from the chyme into the GI 
mucus layers. It also has not been established which type of particle provides the most 
uniform distribution over the absorptive epithelium in the GI tract.  
In this paper, we sought to directly test the GI distribution of particles that were 
carefully confirmed to possess either strongly mucoadhesive or non-mucoadhesive 
surfaces. We hypothesized that particles smaller than the mucus mesh spacing and with 
non-mucoadhesive surfaces would penetrate the thick mucus barrier in the GI tract, 
leading to a more uniform delivery of the particles to the absorptive epithelium in healthy 
animals. We also tested these particle types in an animal model of ulcerative colitis (UC), 
a subset of inflammatory bowel disease (IBD) characterized by disruption of the 
epithelial barrier, increased mucus secretion, and increased inflammation, with the 
hypothesis that the non-mucoadhesive particles may more effectively penetrate through 
the mucus barrier and enter into the diseased tissues of the GI tract.  
To test our hypotheses, we prepared nanoparticles of various sizes that possessed 
either unmodified hydrophobic surfaces, or hydrophilic, neutrally charged surfaces 




mouse GI mucus ex vivo that the unmodified nanoparticles were mucoadhesive 
(mucoadhesive particles, MAP), whereas the PEG-coated particles were non-
mucoadhesive (mucus-penetrating particles, MPP).  Subsequently, we administered MAP 
and MPP to mice by oral gavage, ligated intestinal loops and by rectal enema, and 
observed their distribution in the jejunum, ileum, and colon. We further compared MAP 
and MPP distribution in inflamed regions of the small intestine and the associated 
ulcerated colonic tissue regions in two common mouse models of UC.  
3.2 Materials and Methods 
3.2.1 Animal model 
Female 6-8 week old CF-1 mice were purchased from Harlan (Indianapolis, IN). Mice 
were placed on liquid diet for 24 h and starved for 24 h to produce reduced amounts of 
softer, more human-like feces, as opposed to the dry, hard pellets normally produced by 
mice. To induce TNBS-colitis, mice were anesthetized with isoflurane and dosed rectally 
with 0.125 mg/g of 2,4,6-trinitrobenzenesulfonic acid (TNBS, also known as 
picrylsulfonic acid, Sigma-Aldrich) in 50% ethanol as previously described 174. To induce 
DSS-colitis, mice were given 4% w/v dextran sulfate sodium (DSS, Sigma-Aldrich) in 
their drinking water for four days, as previously described 175. Only mice that lost at least 
5% of their body weight, a common measure of disease induction, were used 174. These 
procedures reliably produced mice with colorectal tissue with clear signs of 
inflammation, including thickening of the mucosa and loose stool. Mice with DSS- and 
TNBS-induced colitis were allowed access to food and water ad libitum. All procedures 




3.2.2 Nanoparticle formulation 
Fluorescent, carboxylate-modified polystyrene nanoparticles (PS-COOH) of various sizes 
(40 nm, 100 nm, 200 nm, 500 nm) were purchased from Molecular Probes (Eugene, OR) 
and used as model conventional mucoadhesive particles (MAP). To produce mucus-
penetrating particles (MPP), PS-COOH nanoparticles were densely coated with 
poly(ethylene glycol) (PEG), as previously described 176. Briefly, 5 kDa methoxy-PEG-
amine (Creative PEGworks), N-Hydroxysulfosuccinimide (Sigma), and 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC, Invitrogen) were dissolved in 200 mM borate 
buffer and added to PS-COOH to facilitate coupling of carboxylic acid and amine groups. 
Nanoparticle size was characterized using dynamic light scattering (90° scattering angle), 
and ζ-potential was determined via laser Doppler anemometry with a Zetasizer Nano 
ZS90 (Malvern Instruments, Southborough, MA) (Table 3-1). We have previously found 
that a near-neutral ζ-potential for these particles indicates that the surface is sufficiently 
coated with PEG to rapidly penetrate human cervicovaginal mucus (Table 3-1) 61. All 
measurements were performed at 25°C and according to instrument settings. 
3.2.3 Nanoparticle distribution in the mouse small intestine and colorectum 
Nanoparticles were diluted to 0.2 – 0.02% w/v in water for distribution studies depending 
on particle size and mode of administration. For nanoparticle distribution in the small 
intestine, 50 µl of nanoparticles suspended in deionized (DI) water were administered via 
oral gavage. Sections of the jejunum were excised 1 h (colitis) and 2 h (healthy) post 
administration, and sections of the ileum were excised 6 h post administration and 
subsequently flash frozen in Optimal Cutting Temperature compound (OCT). For 




ileum was exposed from a small incision in the abdomen. A 2 cm region was tied off 
using surgical sutures, and 200 µl of fluid was injected into the loop using a syringe. The 
loops were excised 30 min after administration of nanoparticles and frozen in OCT. To 
assess colorectal distribution, nanoparticles were suspended in DI water as an enema 
vehicle. For transverse sections, 20 µl of nanoparticle solution was administered to mice 
under isoflurane anesthesia. After 5-10 min, their colorectal tissues were excised and 
immediately frozen in OCT. For all tissues, sections were cut 6 µm thick using a Leica 
CM-3050-S cryostat. The tissue sections were briefly fixed in 10% formalin, air dried, 
and stained with ProLong Gold antifade reagent with 4',6-diamidino-2-phenylindole 
(DAPI). Sections were imaged using an inverted epifluroescence microscope (Zeiss Axio 
Observer).  
For surface coverage measurements in the jejunum, 50 µl of nanoparticles 
suspended in DI water were administered via oral gavage, and tissues removed after 2 h. 
The tissues were then sliced open longitudinally and flattened between two glass slides to 
expose the epithelial folds (colon) or villi (jejunum), as previously described 177. For 
surface coverage measurements in the colorectum, mice were given a 200 µl DI water 
enema prior to nanoparticle administration to remove remaining pellets and ensure 
maximum tissue surface exposure. After 10 min, to ensure that all excess enema fluid 
was either expelled or absorbed by the epithelium, 50 µl of nanoparticle solution was 
administered rectally, and the tissues were excised within 5-10 min. Tissues were imaged 
using an inverted epifluroescence microscope (Zeiss Axio Observer). Control tissues 
(mice receiving no nanoparticles) were imaged to determine tissue background 




background. For quantification, 6 images were obtained at regular intervals along the 
tissue surface. The images were threshholded and the % coverage was quantified using 
ImageJ as previously described 177. Data represents the average for n ≥ 3 mice ± the 
standard error of the mean.  
3.2.4 Ex vivo tracking of nanoparticles in small intestinal and colorectal mucus of mice  
Mice were prepared as described above. On day 3 after TNBS treatment (UC colon) or 
after 3 days of liquid diet and a 24 h starvation period (healthy small intestine), ex vivo 
tracking experiments were performed as previously described 61, 178. Briefly, the small 
intestine or colorectum was excised, longitudinally sliced open, and a 1 cm segment of 
tissue was placed in a custom-made 0.5 x 1 cm chamber. A volume of 0.5 µL of 
nanoparticles of various sizes (diluted to 0.02−0.08% w/v) was carefully pipetted on top 
of the mucus coating the tissues. The wells were then sealed by placing a cover slide was 
on top of the tissue and affixing it using superglue. Movies were obtained using an 
inverted epifluorescence microscope with a 100×/1.46 NA oil-immersion objective. 
Movies were taken using an EMCCD camera (Evolve 512; Photometrics) for 20 s at 
temporal resolution of 66.7 ms. Nanoparticle positional data was obtained using 
Metamorph software and the resulting trajectories were analyzed using MATLAB. At 
least 100 nanoparticles of each size and type were tracked for 50 frames or more to obtain 
nanoparticle mean square displacements (MSD) as a function of timescale calculated as 
<Δr2(τ)> = [x(t+τ)-x(t)]2 + [y(t+τ)-y(t)]2 178-181. Our prior work has found that static error 
can be estimated to be 20 nm, much smaller than the size of the nanoparticle 





3.3.1 Distribution of orally-administered MAP and MPP in the small intestines of healthy 
mice. 
We first performed ex vivo multiple particle tracking (MPT) experiments, as 
previously described 61, to confirm that our model mucoadhesive particles (MAP) were 
adhesively trapped in mucus layers coating freshly excised mouse small intestine tissue. 
The trajectories of 200 nm MAP indicated adhesive immobilization (Fig 3-1A). In 
contrast, the trajectories of similarly-sized MPP indicated that MPP freely diffused in the 
mucus layers coating mouse small intestine tissue (Fig 3-1A). We then sought to 
determine whether adhesive interactions with small intestine mucus would impact 
nanoparticle delivery following oral administration by gavage. We used small gavage 
fluid volume (50 µL) to administer MAP and MPP to minimize volume-related artifacts 
183. As shown in Figure 3-1B, adhesion of MAP to luminal mucus layers resulted in 
exclusion of these particles from most of the epithelial surface (black in the image). In 
contrast, MPP were found distributed over much more of the epithelial surface, such that 
the impression of the flattened villus tips could be visualized to be nearly completely 
surrounded by MPP (Fig 3-1B). We then quantified the epithelial surface area covered by 
nanoparticles, and found that MPP covered 74 ± 4% of the epithelial surface of the 
jejunum, compared to only 35 ± 7% by MAP (Fig 3-1C).  
Using the same oral administration methods, we then examined the cross-
sectional distribution of the particles. We found that the adhesive MAP were clumped 




3-2). In contrast, MPP distributed evenly throughout the tissue in both the jejunum and 
ileum, even though a small gavage fluid volume was used (Fig 3-2). 
3.3.2 Impact of fluid volume and mode of administration on MAP and MPP distribution 
in the small intestines of healthy mice. 
One challenge with interpreting and comparing literature reports of oral 
administration of nano- and microparticles is that the experimental protocols often differ 
significantly. We thus investigated the effects of fed state, administration method (oral 
gavage vs. intestinal loop), and gavage fluid volume on the GI distribution of MAP and 
MPP. Animals are almost always starved prior to oral administration experiments to 
avoid the confounding changes in transit time and absorption attributable to varied GI 
content. As shown in Figure 3-3A, not only was there little apparent effect on intestinal 
distribution of MPP after oral gavage to mice in the “fed” state, but the difference in 
distribution between co-administered MAP and MPP appeared even more pronounced in 
the fed state compared to the starved state. In the area close to the lumen (L), outlined at 
10x magnification by a pink box and then shown at 20x, MAP were found in large 
aggregates sometimes colocalized with some MPP, whereas MPP were also dispersed 
between the villi. In the area far from the lumen and among the villi, outlined at 10x 
magnification by a yellow box and then shown at 20x, MAP were essentially absent in 
the villi, whereas MPP were dispersed throughout and between the villi (Fig 3-3A). Thus, 
in the fed state, in contrast to MAP, non-adhesive MPP appeared to leave the digesta, 
penetrate the entire mucus barrier, and become well distributed on the epithelial surfaces. 
 We next investigated whether the high fluid volumes often used with intestinal 




administering particles in a large volume of fluid, that can distend the intestines and 
potentially cause viscous fingering through the mucus barrier 4, would enhance MAP 
distribution throughout the small intestine. As expected, filling the intestine with fluid 
containing MAP in an ileal loop model led to dispersion of MAP throughout the intestine 
and between the villi (Fig 3-3B). The distribution of MAP was very similar to MPP 
administered to intestinal loops (Fig 3-4).  Similarly, when we administered MAP by oral 
gavage in 5-fold higher fluid volume (250 µL), although MAP appeared to aggregate to 
some extent, they became distributed in the jejunum and ileum as though the mucus 
barrier was not present (Fig 3-3B). Overall, the small intestine distribution of MAP in an 
intestinal loop model, and after high volume gavage of MAP (that would be impractical 
to scale to humans), was very similar to distribution of MPP, and was in stark contrast to 
the distribution of MAP administered by gavage in low fluid volume (Fig 3-2). 
3.3.3 Distribution of MAP and MPP in the colorectum of healthy mice.  
Prior to in vivo experiments to investigate MAP and MPP distribution in the 
colorectum of healthy mice following administration by enema, we first confirmed that 
MAP, regardless of particle diameter, were adhesively trapped in the mucus layers 
coating colorectal tissues freshly prepared ex vivo, whereas MPP <230 nm in diameter 
rapidly diffused through mouse colorectal mucus, as indicated by their trajectories (Fig 3-
5). With this confirmation, we compared MAP and MPP distribution on the colonic 
epithelium when administered a hypotonic enema vehicle that causes osmotically-
induced fluid absorption by the colonic tissue and, thus, fluid advection toward the 
epithelium 61.  MAP were trapped and aggregated within colorectal mucus in vivo 




colorectal lumen (Fig 3-5). In contrast, MPP uniformly coated the epithelial surface of 
the colorectum within only a few minutes after administration. MPP 40 nm and 100 nm 
in size reached all of the deep, folded surfaces, evenly coating the colorectal epithelium 
(Fig 3-5). MPP 200 and 500 nm in size also provided improved distribution compared to 
similarly sized MAP (Fig 3-5). However, 200 and 500 nm MPP did not distribute 
throughout the colorectal epithelium as uniformly as 40 and 100 nm MPP (Fig 3-5), a 
result consistent with the rapid diffusion of 40 and 100 nm MPP observed by ex vivo 
multiple particle tracking on freshly excised mouse GI tissue.  
We then sought to quantify the colorectal distribution of MAP and MPP in the 
mouse colorectum after administration by hypotonic enema. MAP of all sizes were found 
to associate with luminal mucus bundles (Fig 3-6A), limiting the apparent colorectal 
surface coverage of 40, 100, 200 and 500 nm MAP to 39 ± 4%, 38 ± 2%, 38 ± 3%, and 
36 ± 3%, respectively (Fig 3-6B).  In contrast, MPP reached more of the colorectal tissue 
surface, with overall surface coverage decreasing as particle size increased (Fig 3-6A). 
MPP 40 nm in size provided a nearly uniform coating of the colorectal tissue surface (84 
± 1%), and while a significant portion of 100 nm MPP reached the tissue surface (leading 
to 80 ± 1% coverage of the colorectal surface), some 100 nm MPP remained in the 
luminal mucus gel (Fig 3-6A). MPP with diameters of 200 and 500 nm MPP were also 
found on the colorectal tissue surface (76 ± 2% and 55 ± 3% of the tissue surface, 
respectively; Fig 3-6B), however, an increasing amount appeared to be associated with 
the luminal mucus plug as MPP size increased (Fig 3-6A). Penetration of colorectal 
mucus by larger MPP was likely hindered by steric interactions with the mouse colorectal 




using ex vivo MPT (Fig 3-5 and 61), as well as with the cross-sectional colorectal MPP 
distribution observed in Figure 3-5.   
3.3.4 MAP and MPP transport in colorectal mucus from mice with TNBS-induced colitis.  
Mucus hypersecretion and degradation is associated with UC, which may impact 
the structure of the mucus mesh and potentially alter the relative adhesive character of 
MAP or non-adhesive character of MPP. Thus, we first used MPT to quantify the 
transport of MAP and MPP in colorectal mucus on freshly excised ex vivo colorectal 
tissue obtained from mice with TNBS-induced colitis. The ensemble-averaged mean 
square displacement (<MSD>) of MAP in UC mouse colorectal mucus was decreased by 
>8,000-fold compared to the theoretical MSD of similarly sized nanoparticles in water, 
regardless of size, indicating adhesive immobilization (Table 3-2, Fig 3-7A). In contrast, 
MPP up to 200 nm in size readily diffused in colorectal mucus from mice with UC. Steric 
trapping of 500 nm MPP was observed in UC colorectal mucus, resulting in a low 
<MSD> that was similar to all sizes of MAP (Fig 3-7A). The distribution of the 
individual particle MSD values indicated that 100 nm MPP were uniformly diffusive, and 
>30% of 200 nm MPP diffused rapidly in UC colorectal mucus (Fig 3-7B). The <MSD> 
of 100 and 200 nm MPP in UC mucus were 2- and 25-fold increased, respectively, in UC 
colorectal mucus compared to in colorectal mucus from healthy mice (Table 3-2), 
indicating an increase in the overall pore size in UC colorectal mucus compared to 
healthy mouse colorectal mucus.  
3.3.5 Distribution of MAP and MPP in the GI tract of mice with induced colitis. 
After confirming that MAP were adhesively immobilized in GI mucus from mice 




MPP in the colorectum of mice with UC. Similar to the distribution observed in the 
healthy mouse colorectum, MAP of all sizes were adhesively trapped in mucin bundles in 
the colorectum of mice with TNBS-induced UC, thus limiting distribution over the tissue 
surface (Fig 3-8A). Mucin bundling induced by MAP also trapped some MPP that were 
co-administered with MAP, as evidenced by the low amount of individual MAP 
compared to co-localized MAP and MPP, and MPP alone (Fig 3-8A). Regardless, MPP 
of all sizes distributed over more of the colorectal tissue surface in both healthy mice and 
mice with UC (Fig 3-8A). There was an increase in the colorectal surface coverage by 
200 nm MPP in mice with UC compared to in healthy mice (Fig 3-8A), which  
is consistent with the increase in the fraction of diffusive 200 nm MPP observed in UC 
mucus compared to in healthy colorectal mucus in the ex vivo MPT experiments (Fig 3-
7B).  
We next sought to test whether inflammation in the small intestine associated with 
IBD would impact the distribution of MAP and MPP after oral administration, but 
TNBS-induced colitis only locally affects the colorectum. It is generally accepted that 
DSS-induced colitis causes inflammation and mucus hypersecretion in the small intestine 
175, so we used this model of induced colitis to observe nanoparticle distribution in the 
inflamed small intestine after oral administration. Inflammation was evident by the lack 
of organized alignment of cell nuclei and general damage to the small intestine villi 
compared to healthy mice.  We found that, similar to our findings in healthy mice, 200 
nm MAP aggregated in the lumen of the inflamed small intestinal regions, whereas MPP 




UC is also characterized by increased epithelial permeability and ulceration, such 
that nanoparticle uptake into the tissue has been hypothesized as a mechanism for 
improved and selective nanoparticle-based drug delivery to treat UC 89, 109, 111, 184-186. We 
hypothesized that the ability of MPP to penetrate the mucus barrier would lead to 
increased accumulation of MPP compared to MAP in the tissue ulcerations. As shown in 
Figure 3-8, co-administration of MAP and MPP to mice by enema provided a stark visual 
contrast between the aggregated and poorly distributed MAP compared to the evenly 
distributed MPP in the healthy mouse colorectum, regardless of nanoparticle size. A 
similar contrast in colorectal distribution was seen for MAP and MPP in the colorectum 
of mice with TNBS-induced UC, and MPP also penetrated into damaged areas of the 
epithelium (Fig 3-9, green arrows) much more efficiently than MAP. MAP were also 
found near damaged areas of the epithelium, but tended to aggregate in the mucus or 
adhere only to the outer cell layer (Fig 3-9, red arrows).  
3.4 Discussion 
Enhancing the uniformity and proximity of drug-loaded particulates to the absorptive 
regions of the GI epithelium may improve both systemic drug absorption and local drug 
delivery for disorders such as IBD. Since most small molecule drugs are hydrophobic, 
strategies such as drug micronization and encapsulation within micro- or nanoparticle 
systems are used to overcome solubility limitations, leading to enhanced drug absorption 
1, 3, 4, 162-164. However, additional barriers to effective drug absorption in the GI tract exist, 
such as the mucus barrier lining the GI tract. Mucus can form multiple low-affinity 
interactions with particulate matter, including hydrophobic interactions, such that most 




mechanisms by which mucoadhesion occurs, including electrostatic interactions and 
polymer interpenetration 9, 71, 72, 83, and these systems are all designed to facilitate strong 
adhesion to mucus. We demonstrated here that conventional hydrophobic mucoadhesive 
particles (MAP) stick to mucus and digesta, resulting in aggregation and limited 
distribution throughout the GI tract after oral and rectal administration. In contrast, non-
mucoadhesive particles that penetrate through small and large intestine mucus (MPP) 
were able to reach nearly the entire tissue surface, which is likely to provide improved 
drug delivery for both local and systemic applications. 
Mucoadhesion, which is generally defined as the interaction between a biological 
or synthetic material and the mucosa 188, is widely employed for drug delivery to mucosal 
surfaces. For example, mucoadhesion of pharmaceutical devices to surfaces that 
experience constant physical stress and drug clearance on the order of seconds to 
minutes, such as the buccal or ocular surfaces, can markedly improve drug delivery 189. 
Also, devices generally larger in size than the thickness of the mucus barrier, such as 
micropatches 190, 191 and large microspheres functionalized with silicon nanowires 192, 
may be able to interact directly with the underlying mucosa to increase residence time in 
the GI tract. The distinction between mucus adhesion and mucosa adhesion is very 
important, and size scale is one factor that determines the efficiency by which a system 
designed to stick to the mucosal epithelium may contact the epithelium, as opposed to 
becoming trapped in the mucus gel instead. This paper shows that a typical mucoadhesive 
micro- or nanoparticle adheres to the luminal mucus gel before reaching the mucosa, 
thereby limiting particle distribution in the GI tract, and likely limiting GI residence time 




present whether MAP or MPP would be retained longer in the GI tract. However, our 
other work in the lung 7 and vagina 177 demonstrated that MPP enter more slowly cleared 
mucus layers, leading to prolonged retention of MPP compared to MAP that stick to the 
luminal mucus layers (note that MAP were called conventional particles, or “CP”, in 
these other papers). Carefully comparing the GI tract residence time of MAP and MPP 
will likely require the use of larger animals with GI transit times more similar to humans, 
such as dogs and pigs 193. In rodents, the rapid GI transit time and production of a 
succession of hard, desiccated pellets (we have observed that mice produce a pellet once 
every 5-10 min) limits the ability to correlate particle retention in the rodent GI tract to 
what would be expected in humans. Assessing GI tract retention in a more 
physiologically relevant animal model is a high priority for future development of MPP 
for GI tract drug delivery.  
It is important to recognize that numerous examples of mucoadhesive micro- and 
nanoparticle systems exist that provided improved drug delivery compared to the 
unencapsulated drug. For proteins where mucoadhesive particle systems have provided 
significantly improved bioavailability, such as insulin 194-198 and calcitonin 196, 199-201, 
encapsulation within the nanoparticle core shields the cargo from degradation in the harsh 
GI environment and can provide sustained release, which likely account for the enhanced 
protein uptake. However, while drug delivery to the GI tract via mucoadhesive particles 
may provide significant advantages compared to administration of unencapsulated drug, 
our work suggests that the extent of the advantage is limited by particle aggregation and 
adhesion to mucus in vivo. In other work, liposomes coated with a commonly used 




GI fluid in vitro, and provided decreased cyclosporine A bioavailability in vivo compared 
to unmodified liposomes 202. Also, the percentage of drug that was absorbed by GI tissues 
was increased when the mucus barrier was degraded prior to oral administration, and 
without an intact mucus barrier, drug delivery was improved for chitosan liposomes 
compared to unmodified liposomes 202. Similarly, incubating invasin-coated PS 
nanoparticles in porcine mucin prior to oral administration led to decreased systemic 
absorption in rats 203. Cell culture studies have also demonstrated decreased uptake of 
mucoadhesive nanoparticles in the presence of mucus 4, 204. Indeed, we demonstrate here 
that MAP, in contrast to MPP, tend to aggregate in the GI tract lumen, where they are 
largely restricted from accessing the absorptive epithelium in the small intestine (both by 
poor surface coverage of the epithelium and by not penetrating to obtain close proximity 
to the epithelium). Our results suggest that drug delivery to the GI tract could be further 
improved by using non-mucoadhesive nanoparticles that distribute throughout the GI 
tract and reach nearly the entire epithelial surface. Definitive illustration of such 
improvement will await future studies seeking to test whether an improvement in 
systemic drug absorption will result from the increased access of drug in MPP to the 
absorptive epithelium, and/or improved efficacy of local drug treatment from increased 
uniformity of drug delivery to the affected tissues and cells.   
We also demonstrate that methods commonly used for testing mucoadhesive 
particle systems may obscure the importance of the mucus barrier in the GI tract. For 
example, intestinal loop models have been used for decades to investigate systemic 
absorption of nanoparticles and drugs. In this model, a portion of the small intestine is 




“loop”, and the test solution of interest is directly infused into the segment of intestine. 
The intestine is then placed back into the abdominal cavity, and absorption is allowed to 
occur over several hours. Using this model, as much as 67% of mucoadhesive 
nanoparticles were found in the blood and various organs, indicating systemic absorption 
205. However, as we demonstrate here, administering fluid into a tied-off loop distends the 
intestine and dilutes the mucus barrier, distributing MAP throughout the entire intestinal 
segment in a manner indistinguishable from MPP.  Other studies have also demonstrated 
elevated absorption of nanoparticles after oral gavage. For example, more than 30% of 
500 nm polystyrene nanoparticles were absorbed after oral gavage in one study 205. 
However, the gavage volume used is important, as similar dilution effects can occur 
when large fluid volumes are gavaged to rodents. For example, Eyles et al. demonstrated 
that, with the same amount of 870 nm PS particles in each dose, a 5-fold increase in 
gavage volume from 0.1 mL to 0.5 mL in rats also caused a 5-fold increase in the 
percentage of nanoparticles found in the bloodstream 183. Thus, when we administered 
MAP by gavage in 5-fold higher volume of fluid (0.25 mL as opposed to 0.05 mL for the 
rest of our studies), it is perhaps not surprising that the small intestinal distribution of 
MAP was indistinguishable from MPP. For most oral drug delivery systems, including 
pills, the driving force for absorption would not be large volumes of fluid forced into the 
intestines, but rather the natural digestive absorption processes, and we demonstrate here 
that MPP have a clear advantage over MAP in being drawn through the mucus barrier 
with the fluid as it is absorbed. We further demonstrated that the stark contrast between 
the small intestinal distribution of MAP and MPP was further enhanced when the 




mucus barrier are transported to the epithelium by the rapid absorption of water by the GI 
tract. This ‘advective’ transport by the flow of water rapidly transports nutrients into the 
highly infolded surfaces between villi. Water absorption increases in the fed state, 
increasing the speed of this advective transport process, and MPP take advantage of this 
process for efficient and uniform drug delivery. In contrast, MAP stick to the outer layers 
of mucus and aggregate in clumps in the center of the lumen, far from the epithelial 
surface.  
For certain applications, such as rectal protection against sexually transmitted 
diseases with microbicides or treatment of UC, colorectal drug delivery may be 
preferable 173, 206-208. Our work indicates that, when administered locally to the 
colorectum via enema, MPP of all sizes tested provided improved distribution over the 
epithelial surface compared to MAP. The hypotonic enema vehicle caused fluid 
absorption by the colorectal epithelium, thus advectively transporting MPP, but not MAP, 
through pores in the mucus mesh to reach the epithelial surface.  We had previously 
observed similar results for MAP compared to MPP in the mouse vagina following 
administration in hypotonic aqueous vehicles 61.  
UC has been associated with mucus hypersecretion and a reduction in mucus 
barrier properties 84, 89, 185. Using MPP of various sizes, we showed that local 
inflammation in the TNBS-induced UC mouse model altered the structure of colorectal 
mucus, allowing larger (200 nm) MPP to penetrate more efficiently compared to 
penetration in healthy mouse colorectal mucus.  However, despite the reduction in steric 
barrier properties, colorectal mucus in TNBS-induced UC maintained adhesivity toward 




nanoparticles preferentially accumulate in inflamed areas of the GI tract due to increased 
mucus accumulation and potentially phagocytosis by macrophages 109, 209. In addition to 
mucus gel hypersecretion, inflammation is associated with breakdown of the adherent 
mucus layer in the colon, which normally excludes bacteria in the healthy colon 210, 
leading to bacterial infiltration into the tissue 113, 211. Increased tissue permeability may be 
a mechanism for selective particle uptake and retention in highly inflamed regions; 
indeed, a measureable decrease in epithelial resistance was observed in tissue biopsies 
obtained from patients with IBD compared to healthy controls, which led to accumulation 
of mucoadhesive particles (microparticles > nanoparticles) in ulcerated tissue regions 112. 
The accumulation increased with increasing disease severity, but the accumulation was 
typically less than 1% of the field of view 112. It was then demonstrated with Ussing 
chambers and tissue biopsies that chitosan-modified poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles had even less penetration into tissue from IBD patients compared to PLGA 
nanoparticles 212. In contrast, PEG-modified PLGA nanoparticles were found in the tissue 
specimens in greater amounts 212. Ussing chamber models may be limited by the fact that 
the tissue and mucus are soaked in media; however, our in vivo results in a mouse model 
of UC confirmed that only small amounts of MAP penetrate into ulcerated tissue regions, 
whereas MPP penetrate the mucus and enter the ulcerated tissue regions in much greater 
amounts. Importantly, the use of a hypotonic enema vehicle likely enhanced MPP 
penetration into ulcerated tissue regions throughout the entire colorectum. 
3.5 Conclusion 
We systematically compared mucoadhesive nanoparticle (MAP) and non-mucoadhesive 




showed that the mucus barrier strongly limited the distribution and proximity of MAP to 
epithelial surfaces in both the small and large intestine. In contrast, MPP evenly coated 
the epithelial surfaces of the GI tract, achieved close contact to the underlying epithelium, 
and penetrated much more effectively into inflamed regions of UC tissues. Thus, the 
formulation of drugs into MPP may provide significant advantages in GI retention and 
drug absorption (owing to increased retention, distribution and proximity to the 
epithelium). In addition, unlike the clear difference of distribution between MAP and 
MPP when orally or rectally delivered, MPP and MAP distribute similarly when 
administered directly to the small intestine, as done in intestinal loop models, or in a high 
volume of gavage fluid. This indicates that care must be taken when choosing 
experimental methods for evaluating nanoparticle delivery to the GI tract, as some 
techniques are not representative of normal GI tract transit. Future studies will determine 
whether the improved mucosal distribution in the GI tract observed with non-
mucoadhesive particles may lead to improved local drug treatments for diseases such as 
UC and colon cancer, improved microbicide-based protection against sexually 















Table 3-1. Size and ζ-potential of various sized MPP and MAP 
used for oral and rectal administration of mice. Values are 
presented as the average of three runs ± SEM. 
Particle Type Size (nm) ζ-potential (mV) 
40nm MAP 56±2 -33 ±0.6 
40nm MPP 60±1 -2.2 ±0.2 
100nm MAP 88±1 -50±0.7 
100nm MPP 120±2 -2.3±0.2 
200nm MAP 190±3 -53±2 
200nm MPP 230±4 -1.9±0.2 
500nm MAP 500±11 -69±3 





Table 3-2. Comparison of ensemble averaged MSD of MPP in colorectal mucus from 
healthy mice and mice with TNBS-induced colitis. Values are representative of n ≥ 3 







100 nm MPP 80 40 2 
200 nm MPP 8,000 300 25 




























Figure 3-1. Distribution of MAP and MPP in the jejunum after low volume oral 
gavage. (A) Trajectories representative of 3 s of movement of 200 nm MAP and MPP 
in mucus on freshly excised mouse small intestine tissue. (B) Distribution of 200 nm 
MAP and MPP on flattened mouse jejunum tissues after oral administration. (C) 
Quantified surface coverage of 200 nm MAP and MPP on flattened mouse jejunum 
tissue. Images are representative of n ≥ 3 mice. White scale bars indicate 300 µm. Data 





Figure 3-2. Distribution of MAP and MPP in the jejunum and ileum after low 
volume oral gavage. Distribution of fluorescent 200 nm MAP or MPP in the healthy 
mouse jejunum and ileum after low volume oral gavage. White scale bars indicate 300 
µm. Images are representative of n ≥ 3 mice. 
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Figure 3-3. The impact of different experimental methods on the distribution of 
MAP and MPP in the jejunum and ileum. Distribution of fluorescent 200 nm MAP 
(red) or MPP (green) in: (A) the jejunum of healthy mice in the fed state after oral co-
administration in a low volume gavage. In the 10x image, “L” denotes the lumen, the 
pink box outlines the luminal area (also shown outlined in pink at 20x), and the yellow 
box outlines the villi region (also shown outlined in yellow at 20x); and (B) the ileum of 
mice in the starved state after direct administration to an ileal loop, or in the jejunum and 
ileum after oral direct administration to an ileal loop, or in the jejunum and ileum after 
oral administration in a high volume gavage. Images are representative of n ≥ 3 mice. 
White scale bars indicate 300 µm and 100 µm for 10x and 20x images, respectively. 
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Figure 3-4. Distribution of MPP ileum after intestinal loop. Distribution of red 
fluorescent 200 nm MPP after direct administration into an ileal loop. White scale bar 
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Figure 3-5. Trajectories in colorectal mucus and distribution of MAP and MPP in 
the mouse colorectum. Trajectories representative of 3 s of movement for 40, 100, 200, 
and 500 nm MAP and MPP in mucus on freshly excised mouse colorectal tissue. Black 
scale bars indicate 1 µm for all trajectories. Distribution in transverse colonic 
cryosections after rectal administration of 40, 100, 200, and 500 nm MAP (red) or MPP 
(green). Cell nuclei are stained with DAPI. White scale bars indicate 300 µm for all 











































Figure 3-6. Quantified colonic distribution of MAP and MPP after rectal 
administration to mice. Distribution on flattened colonic tissue after rectal 
administration of 40, 100, 200, and 500 nm (A) MAP (red) or MPP (green). (B) 
Quantified surface coverage of various sized MAP and MPP on flattened mouse colonic 
tissue. Images are representative of n ≥ 3 mice and 6 images per tissue. White scale bars 
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Figure 3-7. Transport of MAP and MPP in colorectal mucus on freshly excised ex 
vivo tissue from mice with TNBS-induced colitis. (A) Ensemble averaged mean-
squared displacement (<MSD>) as a function of time scale for various sizes of MAP and 
MPP particles, including the theoretical MSD of 100 nm particles in water (W). (B) 
Distribution of the logarithms of individual particle MSD at a time scale of 1 s for various 
sized MAP (□) and MPP (■). Data is calculated as mean ± SEM (≥ 3 individual tissues 






Figure 3-8. Distribution of various sizes of MAP and MPP after rectal co-
administration to mice with TNBS-colitis and after oral co-administration to mice 
with DSS-colitis. Distribution of co-administered, fluorescent MAP (red) and MPP 
(green) (A) on flattened colonic tissue after rectal administration of various sizes (100 
nm, 200 nm, 500 nm) to healthy mice and mice with TNBS-induced ulcerative colitis and 
(B) in the jejunum of mice with DSS-induced colitis after low volume oral co-
administration of 200 nm particles (shown at 10x and 20x magnification). White scale 
bars indicate 200 µm in (A) and 300 µm for the 10x and 100 µm for the 20x images in 








Figure 3-9. Distribution of various sizes of MAP and MPP after rectal co-
administration to mice. Distribution of rectally co-administered, fluorescent MAP (red) 
and MPP (green) of various sizes (100 nm, 200 nm, 500 nm) in the colorectum of healthy 
mice and mice with TNBS-induced colitis. The red arrows highlight aggregates of MAP, 
while the green arrows highlight areas where the MPP have penetrated into the tissue. 
Cell nuclei are stained blue with DAPI. White scale bars indicate 100 µm. Images are 






























4. OPTIMIZING LOCAL AND SYSTEMIC DRUG DELIVERY VIA THE 
COLORECTUM: TUNING ENEMA FORMULATIONS FOR SYSTEMIC OR 
LOCAL APPLICATIONS BY VARYING ION COMPOSITION 
4.1 Introduction  
Delivering drugs to the colorectum can provide several benefits. Systemic 
delivery via the colorectum is commonly used in children and also adults when drugs are 
either poorly bioavailable or oral ingestion is not possible 213-216. Rectal delivery allows 
drugs to reach systemic circulation without degradation due to stomach acid, digestive 
enzymes, and hepatic first-pass metabolism. Colorectal delivery can also provide 
increased local tissue drug concentrations without systemic exposure to large drug doses 
taken orally. Stable, water-soluble drugs can be administered directly to the colorectum in 
aqueous enemas; poorly water soluble and/or easily degraded drugs can be packaged into 
nanoparticles, and then suspended into aqueous enemas. In either case, the enema itself, 
which is often ignored as a formulation component, can be optimized for improving 
colorectal drug delivery. The rational design of enema formulations can improve the 
bioavailability whole bypassing the barriers to oral administration. More effective drug 
delivery to the colorectum has the potential to improve therapy for diseases with local 
manifestations, such as inflammatory bowel disease (IBD) and colorectal cancer, and for 
preventing rectally transmitted infections such as HIV. 
Many functions of the gastrointestinal (GI) tract use bulk fluid flow: in the small 
intestine, many liters of fluid are absorbed to rapidly transport nutrients through the 
mucus barrier covering the villi, and in the colon, additional water is withdrawn to dry 




harnessed for more effective drug delivery. However, nutrients can only be absorbed by 
the GI tract if they can pass through the “filter” formed by highly viscoelastic and 
adhesive layers of mucus. Nutrients, or drug-loaded nanoparticles, that adhere to the 
mucus barrier will be trapped before they reach the epithelium and be rapidly cleared 
along with outermost ‘sloppy’ layers of mucus 4, 9. In contrast, we found that 
nanoparticles engineered to slip through the mucus barrier, or mucus penetrating particles 
(MPP), can be efficiently delivered to the entire colorectal epithelial surface 79. Rapid and 
widespread distribution of MPP was driven by the rapid absorption of water from 
hypotonic vehicles “advectively” transporting MPP to the epithelium much faster than by 
diffusion alone 79. Similarly, we found that hypotonic vehicles induced rapid fluid 
absorption by the vaginal epithelium that rapidly delivered water soluble drugs and MPP 
to the epithelial surface by advection 5, 61. In contrast, MPP administered in isotonic 
vehicles (no fluid absorption) remained in the vaginal lumen and only slowly diffused 
through the mucosal barrier 61. Thus, MPP provide a simple and sensitive method for 
observing the direction of fluid movement induced by the tonicity of the vehicle, as well 
as serving as carriers for improved mucosal drug delivery.  
Here, we investigated the impact of enema composition (osmolality, ion 
composition) on fluid absorption/secretion and drug delivery in the colorectum. We 
explored the full range of hypotonic (pure water, 20 mOsm) to hypertonic (2200 mOsm 
Fleet® enema) as well as solutions that contained sodium or potassium ions. We found 
that the tonicity of a solution depends not only on the osmolality, but also on the ion 
composition as it relates to ion transport processes of the epithelium. Further, the 




enhance various types of drug delivery, whether the goal is systemic absorption or local 
tissue absorption. We demonstrate that a mildly hypotonic, sodium-based enema 
formulated with ion concentrations similar to those in feces (simulated colon solution, or 
SCS), provided enhanced colorectal distribution of both MPP and water soluble drug, 
improved tissue uptake of water-soluble drug, and caused no detected toxic effects in the 
colorectum. In addition, we show that pre-treatment using epithelial-damaging, strongly 
hypertonic enemas causes nanoparticle penetration into colorectal tissue. Our 
investigations illustrate the ability to tune enemas by varying ion content, thus making 
them suitable for local and/or systemic drug delivery.     
4.2 Materials and Methods 
4.2.1 Animal Model 
Rodents are commonly used as animal models for delivery to the gastrointestinal tract. 
However, their defecation rate is much more rapid (every 5-10 min for mice) than typical 
for humans, and their hard, desiccated pellets do not resemble human feces. To simulate 
the softer stool consistency and less frequent defecation rate of humans, female 6-8 week 
old CF-1 mice (Harlan) were starved for 24 h to make the feces softer, more human-like, 
and less abundant. Mice were housed in cages with wire bottoms to prevent coprophagia. 
Various test solutions were administered intrarectally to mice with a Wiretrol 
(Drummond, Inc.) at volumes of 20 µL. Mice were anesthetized with the drop-method 
via isofluorane for shorter times, or injected with 300 mg/kg avertin (2, 2, 2-
Tribromoethanol), using a 20 mg/mL working solution in phosphate buffered saline 




while still anesthetized. All experimental procedures were approved by the Johns 
Hopkins Animal Care and Use Committee. 
4.2.2 Nanoparticle formulation and characterization 
MPP were synthesized as previously described 217. Briefly, fluorescently labeled 
carboxylate-modified polystyrene (PS-COOH) nanoparticles 40 nm in diameter were 
purchased from Molecular Probes (Eugene, OR). To obtain a dense polyethylene glycol 
(PEG) coating, nanoparticles were suspended in 200 mM borate buffer and 5 kDa 
methoxy-PEG-amine was added in excess. N-Hydroxysulfosuccinimide (Sigma) and 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Invitrogen) were subsequently 
added to couple the carboxylic acid on the nanoparticles with the amine group on the 
PEG. Nanoparticle size and ζ-potential were measured in a Zetasizer Nano ZS90 
(Malvern Instruments) after suspending nanoparticles in 10 mM NaCl solution, via 
dynamic light scattering (90° scattering angle) and laser Doppler velocimitry (or 
anemometry). Measurements were taken at 25°C according to instrument settings. A 
near-neutral ζ-potential indicates sufficient PEG surface coverage to make nanoparticles 
that penetrate mouse colorectal mucus (MPP) as previously described 79. 
4.2.3 Enema formulations 
To obtain sodium-based solutions of various osmolalities, concentrated (10x) tris-
buffered saline (Mediatech; 1X TBS in 20 mM tris, 138 mM NaCl, pH 7.4) was diluted 
with DI water. Similarly, to obtain potassium-based solutions (KPO4) of various 
osmolalities, potassium phosphate buffer (1 M K2HPO4  pH 5.5, Sigma) was diluted with 
DI water (e.g. 150 mOsm buffer was made by diluting 1M K2HPO4 ~12 fold). The 




chloride, dibasic potassium phosphate and monobasic potassium phosphate (Sigma) in DI 
water at the following ion concentrations: 75 mM K+, 25 mM Na+, 35 mM Cl-, 30 mM 
PO4
3-, and 25 mM CO3
2- 40. Solution osmolality was measured with a vapor pressure 
osmometer (Wescor Vapro) and measurements were reported as mean ± SEM for n = 3 
measurements. Fleet® enema solution and Fleet® Naturals were purchased over the 
counter, and all enema solutions were sterile-filtered through a 0.2 µm filter prior to use 
in vivo.  A 5% w/v glycerol gel was obtained by mixing the universal placebo 
hydroxyethylcellulose (HEC) gel (ReProtect, Inc.) with glycerol. The glycerol gel and 
Fleet® were serially diluted in DI water before measurements in the osmometer and 
osmolality was extrapolated from the obtained data points. Ion concentrations and 
osmolalities of the various formulations are listed in Table 4-1.  
4.2.4 Nanoparticle and free drug distribution on tissues 
MPP 60±1 nm in (hydrodynamic) diameter were diluted 1:10 in TBS and KPO4 buffers 
of various osmolalities to make a range of sodium-based and potassium-based buffered 
solutions. To observe the colorectal distribution of anti-retroviral drug tenofovir (9-(2-
Phosphonyl-methoxypropyly)adenine, TFV) now in clinical trials for preventing rectal 
transmission of HIV, fluorescein isothiocyanate (FITC) was covalently reacted to the 
amino group on the purine ring of TFV. FITC-labeled TFV (FITC-TFV) was then 
dissolved 1:10 with unmodified TFV in the various solutions at an overall concentration 
of 1% (w/v), the concentration of TFV tested in the (moderately successful) CAPRISA 
004 trial. Mice were anesthetized using isofluorane during administration to ensure that 
the enema fluids would not be immediately expelled. To obtain cross-sectional images 




intrarectally to mice. The mice were sacrificed after 5-10 min. For distribution post 
Fleet® enema, mice were anesthetized with isoflurane and 200 µL of fleet was 
administered intrarectally. After 10-15 min to allow for fluid expulsion (confirmed 
visually), 20 µL of MPP diluted 1:10 in DI water was administered. Mice were sacrificed 
after 5-10 min. Segments of tissue 1-2 cm in length were flash-frozen in Optimal Cutting 
Temperature (OCT) compound. Transverse sections of tissue 6 µm thick were cut at 
various points along the length of the colorectum using a Leica CM-3050-S cryostat. 
Sections containing nanoparticles were fixed with formalin and stained for cell nuclei 
using ProLong Gold antifade reagent with DAPI (Invitrogen). Sections containing free 
drug were not fixed to reduce quenching of the fluorophore and stained with ProLong 
Gold antifade reagent with DAPI. Fluorescent images were obtained using an inverted 
epifluorescence microscope (Zeiss Axio Observer). To quantify nanoparticle distribution, 
one representative section was chosen per animal, and an outline of the epithelial 
perimeter was drawn. The percent overlap between the perimeter and fluorescence (% 
colocalization of nanoparticles with the epithelial perimeter) due to the presence of 
nanoparticles was then calculated for each image using the JACoP plugin for ImageJ, and 
the average with standard error of the mean (SEM) was reported for n ≥ 3 mice.  
4.2.5 Free drug uptake into plasma after administration to the mouse colorectum 
Mice were anesthetized with avertin, and 20 µL of the various solutions containing 1% 
w/v unlabeled TFV and 1 µL of H3-TFV (1 mCi/ml, suspended in ethanol, Moravek 
Biochemicals) was administered intrarectally. For the t = 0 time point, retro-orbital blood 
collection was used to collect blood immediately after administration of each solution; for 




centrifuged in heparinized tubes to obtain plasma, and 200 µL of plasma was dissolved in 
5 mL of SolvableTM and bleached using hydrogen peroxide. 500 µL of 
plasma/SolvableTM solution was added to 10 mL of Ultima Gold, and H3 content was 
analyzed using a scintillation counter. Concentrations were calculated using a calibration 
curve of free H3-TFV. Separate standard curves for high and low count samples were 
made by serial dilution of H3-TFV. The concentrations of H3-TFV in the plasma samples 
were estimated using the standard curves, and the total drug concentration was calculated 
assuming that the H3-TFV and TFV were absorbed similarly in the colorectum.  
4.2.6 Pharmacokinetic studies of free drug in the mouse colorectal tissue 
Mice were anesthetized with avertin, and 20 µL of the various solutions containing 1% 
(w/v) unlabeled TFV and 1 µL H3-TFV (1 µCi/mouse) was administered intrarectally to 
mice. Colorectal tissue was harvested at 5 min, 30 min, 1 h, 2 h, and 4 h time points and 
processed as described above. H3 tissue content was measured using a scintillation 
counter and normalized based on individual tissue weights. Values were obtained from n 
= 5 mice, and the highest and lowest values were removed from each group to obtain n = 
3 per time point for each solution used.  
4.2.7 Toxicity of enema formulations in the mouse colorectum 
Mice were anesthetized with avertin, as described above, and 50 µL of tap water, SCS, or 
Fleet® was administered as an enema. Mice were kept in supine position for 15-30 min 
prior to sacrificing them and excising the tissues. For histological analysis, tissues were 
fixed in formalin and taken to the Johns Hopkins Medical Institutions Reference 




eosin (H&E) staining. Images were obtained using a light microscope with a 10×/0.25 
NA objective (Nikon E600).  
4.3 Results 
4.3.1 Effect of enema osmolality and ion composition on colorectal MPP distribution  
We first investigated the effects of altering enema sodium concentration on MPP 
distribution in the mouse colorectum. It was evident that sodium-based enemas below a 
certain osmolality (~450 mOsm, ~210 mM NaCl) induce fluid absorption that results 
since MPP became uniformly distributes on essentially the entire the epithelial surface 
(Fig 4-1A). In contrast, sodium-based enemas with osmolality >350 mOsm caused fluid 
secretion and bowel distension, resulting in MPP remaining more centrally located in the 
lumen, rather than approaching close proximity to the epithelial surface (Fig 4-1A; 450, 
600, 860, and 2200 mOsm). We next quantified MPP surface coverage as a function of 
absorption or secretion inducing formulations 61. We found that MPP administered in 
sodium-based enemas with osmolalities below 450 mOsm provided >70% coverage of 
the colorectal epithelium, whereas MPP administered in solutions with an osmolality 
≥450 mOsm did not enter the epithelial folds, reducing their surface coverage to < 45%, 
and as low as 0% when administered in a Fleet® enema (Fig 4-1B). Thus, we estimate 
that the effective isotonic point for sodium-based enemas in the mouse colorectum lies 
between 350 and 450 mOsm.  
Potassium, in contrast to sodium, is pumped into the lumen of the colorectum, 
creating a potassium gradient opposite to sodium and producing a high potassium/sodium 
ratio in feces 40. This led us to hypothesize that increasing the potassium concentration in 




mOsm potassium buffer that is markedly hypo-osmolal with respect to blood, would be 
expected on the basis of osmolality to induce fluid absorption, but instead this enema did 
not induce absorption (Fig 4-2A). In contrast, a sodium-based enema with the same 150 
mOsm osmolality, induced rapid absorption that advectively transported MPP to coat 
epithelial surface uniformly throughout the colorectum similarly to MPP administered in 
DI water (Fig 4-2A). Based on the drop in tissue coverage, the isotonic (no fluid flow) 
concentration for potassium phosphate was between 20 and 70 mOsm, and colorectal 
tissue coverage decreased as the osmolality of the potassium-based enema solution 
increased above this range (Fig 4-2B).  As shown in Figures 4-1B and 4-2B, the sodium-
based enemas were significantly more effective for achieving maximal tissue coverage by 
MPP.   
4.3.2 Effect of osmolality of sodium-based solutions on colorectal drug distribution 
We demonstrated previously that hypotonic solutions causing advective absorption may 
also be advantageous for improving the distribution of water soluble drugs in the mouse 
vagina, leading to uniform drug delivery to the entire epithelial surface 61. Here, we 
explored colorectal delivery of TFV in a hypotonic enema for HIV pre-exposure 
prophylaxis (PrEP). We fluorescently labeled TFV with FITC (TFV-FITC) and mixed it 
at a 1:10 ratio with unlabeled TFV to visualize distribution. We first compared sodium-
based enemas of varying osmolality: deionized water (20 mOsm), iso-osmolar saline (264 
± 1 mOsm, iso-osmolar to the blood), TBS buffer at the osmolality in isotonic range (450 
mOsm), and slightly hypertonic TBS buffer (650 mOsm) that should induce fluid 
secretion. As shown in Figure 4-3, fluorescently-labeled TFV distribution was consistent 




tissues) was improved by using an absorption inducing enema. Bulk fluid flow 
transported the water-soluble, small molecule drug through the mucus barrier and to the 
epithelium, and also transported the drug deep into the folds of the (collapsed) 
colorectum. 
We then developed an SCS enema formulation that has sodium and potassium 
concentrations similar to those found in feces, which is likely optimal for safe water 
absorption in the colorectum. The osmolality of the SCS was approximately 150 mOsm. 
Since the solution contained both sodium (25 mM) and potassium (75 mM), we 
investigated the individual contributions of these ions to bulk fluid flow. We found that 
fluid absorption only occurred if sodium was present in the solution (Fig 4-4). If sodium 
was removed, leaving potassium unchanged at 75 mM (SCS, K+ only), no fluid 
absorption occurred and TFV-FITC remained in the lumen. In contrast, if potassium was 
removed, leaving sodium unchanged at 25 mM (SCS, Na+ only), fluid was rapidly 
absorbed by the colorectal epithelium, distributing TFV-FITC throughout all of the folds 
of the mouse colorectum (Fig 4-4).  
4.3.3 Effect of tonicity on colorectal drug uptake into plasma and tissue 
We previously documented that very hypotonic delivery of a water soluble drug led to 
reduced vaginal retention, likely due to the drug being driven advectively all the way 
through the epithelium to reach systemic circulation 61. Here, we investigated the effect 
of enema tonicity on movement of drugs from the colorectal lumen into the plasma. We 
compared drug delivered in a variety of solutions, including: tap water, SCS, TBS (a 
sodium chloride based tris buffer) in isotonic range (450 mOsm), and the highly 




solution containing 5% glycerol in DI water, which is the concentration of glycerol used 
in the reduced-glycerol TFV gel formulation now being tested in clinical trials for rectal 
PrEP 218. No TFV was detected in the plasma after 30 min if administered in isotonic and 
mildly hypotonic SCS solution; however, 3H-TFV could be found in the plasma 30 min 
after enema administration in very hypotonic (DI water) as well as very hypertonic 
(Fleet®) solutions (Table 4-2).   
To investigate how enema composition impacts drug levels in the tissue, we 
compared the amount of 3H-TFV associated with colorectal epithelial tissue when 
administered in the same set of solutions. Based on published cell migration data and the 
number of cell layers these cells need to ascend through the crypts in the mouse 
colorectum, we calculated that the surface epithelial layer, which would absorb drug, 
renews approximately every 2 h 219, 220. For this reason, we assessed tissue concentration 
up to 4 h, at which time TFV tissue concentrations became low and indistinguishable 
between the different solutions. The initial tissue TFV concentrations were highest when 
administered in Fleet® and in SCS compared to administration in isotonic (450 mOsm) 
TBS. But at 2 h, tissue concentrations of TFV administered in Fleet® or isotonic TBS 
were significantly lower than when administered in SCS (Fig 4-5). The area under the 
curve (AUC) for TFV administered in SCS, isotonic 450 mOsm TBS, Fleet® enema, and 
5% glycerol gel were 330, 120, 72, and 21 µg·h/g, respectively. Even though the 5% 
glycerol gel was only moderately hypertonic, it decreased the amount of TFV taken up by 




4.3.4 Toxicity of enema formulations 
Previous results have shown that hypertonic vehicles (gels, lubricants, enemas, etc.) are 
toxic to the human colorectal epithelium 221. We investigated acute tissue effects of 
hypotonic and hypertonic enemas. We compared tap water (strongly hypotonic), strongly 
hypertonic Fleet®, and our moderately hypotonic SCS enema in the mouse colorectum. 
As shown in Figure 4-6, Fleet® enema caused distension and epithelial disruption (red 
arrows) within 10 min of administration. In addition, the damage induced by the Fleet® 
enema allowed nanoparticles to penetrate into the tissue regions where the epithelial 
integrity was compromised (Fig 4-6B), which may be useful for other drug delivery 
purposes, but not for prophylaxis. Tap water and moderately hypotonic SCS did not 
induce any detectable epithelial damage (Fig 4-6A).  
4.4 Discussion 
The human colon absorbs 1.4-1.8 L of water every day, driven by active ion transport 222. 
Water absorption is accomplished by electrogenic 3Na+/2K+ ATPase pumps in the 
basolateral membranes, and high conductance sodium, potassium, and chloride channels 
in the apical membrane of epithelial cells. This robust physiological mechanism provides 
an opportunity to optimize fluid absorption to provide more effective colorectal drug 
delivery. We have previously demonstrated that MPP, which rapidly diffuse through 
mouse colorectal mucus, have enhanced distribution when administered hypotonically in 
the colorectum 79. Unlike model MPP that neither entered the epithelium nor were drawn 
through epithelial at short time points, small molecule drugs can be rapidly drawn into 
and through the epithelial layer 61. Thus, strongly hypotonic solutions, such as DI water, 




solutions such as Fleet can also cause drug to reach systemic circulation (Table 4-2) 133, 
and thus, to achieve setmatic drug delivery, either strongly hypertonic or hypotonic 
solutions can therefore be used for rectal administration. A moderately hypotonic enema, 
in contrast, resulted in no detectable rapid systemic drug absorption (Table 4-2), but 
showed optimal tissue drug levels compared to isotonic and hypertonic formulations. In 
humans, Leyva et al showed that systemic drug levels are highest when using tap water 
(strongly hypotonic) and similarly high in a iso-osmolar enema (300 mOsm, a 
formulation that likely causes moderate fluid absorption in the human colon), while Fleet 
® (strongly hypertonic) resulted in significantly lower systemic drug absorption 133. 
Differences in systemic drug absorption in humans compared to our murine model were 
likely due to the differences in colorectal surface area exposed to the enema formulations 
(higher area exposed in mice than humans). Fleet ® damage may have caused a 
temporary increased permeability in the mouse tissue, and since a relatively larger area 
was affected, significant amounts of drug were able to reach systemic circulation. Leyva 
et al reported that tissue concentration were highest in the iso-osmolar (mildly hypotonic) 
formulation, which correlates with our findings in mice 133.  
For certain applications, systemic delivery is desirable. Rectal delivery has long 
been used to administer medications, such as anti-arthritic, anti-emetic and anti-
angiogenic agents, to the systemic circulation 213-216. Most of these medications have 
improved bioavailability when administered intrarectally, which avoids first-pass 
metabolism and degradation by stomach acid and digestive enzymes. Our findings 
indicate that both strongly absorbing and secreting enemas cause detectable systemic 




hypo- or hypertonic, respectively. However, the toxicity induced by advectively secreting 
(hypertonic) enemas in the colorectum may limit the utility of hypertonic enemas, 
particularly if epithelial toxicity would be detrimental. On the contrary, extremely 
hypotonic enemas may be able to transport drug through the epithelium by both 
paracellular and transcellular fluid absorption and deliver drug to the blood that can 
increase drug plasma levels. The previously mentioned clinical data also suggest that 
strongly hypotonic delivery is favorable for systemic delivery, and intestinal epithelial 
cells show increased transport of hydrophilic molecules when the molecules are applied 
in a 50% hypotonic solution 133, 223. A strongly hypotonic enema formulation may thus be 
optimal for systemic drug delivery via rectal administration 
When high tissue drug levels and low systemic drug exposure are desired, mildly 
hypotonic solutions may be optimal. These solutions can provide robust fluid flow and 
result in increased local drug levels, while avoiding overly rapid trans-epithelial 
advection and systemic absorption (Table 4-2). Sodium drives fluid absorption in the 
colorectum as long as levels are below 205 mM NaCl (450 mOsm) in the mouse, similar 
to the 220 mM NaCl (theoretical osmolality: 440 mOsm) found to cause fluid secretion in 
humans 224. Potassium, on the other hand, seems to induce colorectal fluid secretion even 
at very low levels. By varying the amounts of each of these two ions, optimal 
concentrations can be found that lead to the highest drug tissue levels. Tissue levels may 
depend on the interaction of a specific drug with mucus and the epithelium, and enema 
products could be fine-tuned by varying potassium and sodium concentrations 11, 16, 224. 
An enema with only mild advective absorption can provide improved colorectal drug 




(Table 4-2, Fig 4-6). Our SCS matches ion concentrations found in feces, making it an 
optimal starting point due to a low chance of causing toxicity while still inducing 
sufficient advective fluid absorption to create rapid local drug levels and uniform 
distribution. 
An especially useful application for rectal drug delivery is HIV PrEP. Rectal risk 
for HIV transmission is 10 – 20 fold higher than vaginal transmission, and enema use is 
widespread for cleansing the bowel prior to receptive anal intercourse (RAI) 117, 131, 218, 
225-229; a microbicide-loaded enema would thus require minimal behavioral changes. 
Currently available OTC enema formulations like Fleet, as well as the tenofovir (TFV) 
gels now in clinical trials 221, 230, are hypertonic in the colon, and induce rapid secretion of 
fluid that likely opposes effective drug delivery 61. Moreover, hypertonic formulations 
cause epithelial toxicity that may significantly increase susceptibility to infection, as 
indicated  by the increased delivery of particulates (similar to HIV in size and surface 
properties, unpublished observations) to penetrate into epithelial tissue when they are 
damaged by Fleet® (Figure 4-6B) 129, 221, 231. To provide maximal protection drugs such as 
TFV must be effectively delivered to all of the susceptible cells and tissues, including 
deep into the folded surfaces of the colorectum without inducing epithelial toxicity, a task 
that unlikely to be achieved with current microbicide formulations 5, 61, 230. A hypotonic 
enema vehicle may provide the desired uniform coverage of drug or drug-loaded MPP of 
the epithelial surface of the colorectum while minimizing epithelial damage.  
In addition, the hypotonicity could be tuned based on whether or not systemic 




formulation used by Leyva et al could provide both high systemic and high local drug 
levels, while SCS could provide only high local and low systemic drug exposure 133.  
While epithelial toxicity is undesirable in PrEP, it may be advantageous for other 
applications. A strongly hypertonic enema could be used as a pre-treatment to 
hypotonically delivered nanoparticles that could then penetrate deep into the damaged 
tissue (Fig 4-6B). Tissue penetration may in turn improve drug uptake into systemic 
circulation as well as local tissue uptake. In addition, increased inflammation and tissue 
damage may provide a way to target the immune system via the rectal route. Nano- or 
microparticles could be taken up by the immune cells residing in a tissue that has 
received “danger signals” through Fleet® exposure. The exposure of vaccine-loaded 
nanoparticles to increased numbers of immune cells present could potentially enhance the 
effectiveness of rectal vaccines, such as those currently under investigation to prevent 
STIs and other mucosal infections 232-235.  
4.5 Conclusion 
Systemic delivery via the colorectum is commonly used in children and for medications 
rapidly degraded in the GI tract. Local delivery is preferred at the mucosal surfaces when 
treating and preventing diseases that locally manifest at these surfaces. Here, we report 
that hypotonic, sodium-based enemas improve the distribution of MPP and hydrophilic 
free drugs on the colorectal epithelial surface compared with isotonic and hypertonic 
enemas and potassium-based enemas. We demonstrate that enema formulations can be 
tuned to cause drugs to rapidly reach systemic circulation or remain local in the tissue by 
varying the ion content: Hydrophilic free drug was rapidly taken up into systemic 




moderately hypotonic enema (SCS) significantly improved local drug levels and reduced 
systemic exposure. We also found that hypotonic enema formulations caused no detected 
epithelial damage, while hypertonic enemas significantly damaged the colorectal 




Table 4-1. Ion concentrations and osmolalities of various formulations. Osmolalities 





















1x TBS 70 0 0 70 0 0 N 260 ± 20 
SCS 25 75 30 35 25 0 N 150 ± 1 
SCS K+ 
only 
0 75 30 35 0 0 N 130 ± 1 
SCS, Na+ 
only 
25 0 0 0 25 0 N 55 ± 1 
0.9 % 
saline 
150 0 0 150 0 0 N 260 ± 1 
1.5x TBS 205 0 0 205 0 0 N 450 ± 2 
5% 
glycerol 




150 0 0 150 0 5 Y 760 ± 3 










Table 4-2. Plasma levels of TFV after administration in various enema solutions. 
Amount of TFV present in 200 µL of plasma 0 min and 30 min after administration to 
mouse colorectums. 1% TFV (1:100 H3-TFV:TFV) was administered in DI water (20 
mOsm), TBS (450 mOsm), 5% glycerol (600 mOsm) and Fleet® (2200 mOsm) enema. 
Total amounts were calculated assuming tritiated and unlabeled TFV entered circulation 
at the same rate. Studies were performed in n ≥ 5 mice. 
 
Time after dosing 
0 min 30 min 
Formulation 
(osmolality) 
TFV (µg) # signal/# total TFV (µg) # signal/# total 
DI water 
20 mOsm 
0 ± 0 0/5 7.4 ± 3.4 6/8 
SCS 
150 mOsm 
0 ± 0 0/5 0 ± 0 0/5 
1.5x TBS 
450 mOsm 
0 ± 0 0/5 0 ± 0 0/5 
5% Glycerol in DI water 
600 mOsm 
0 ± 0 0/5 0.1 ± 0.1 1/5 
Fleet® enema 
2200 mOsm 







































































Figure 4-1. Distribution of MPP administered in sodium-based solutions with 
various osmolalities. (A) Distribution of 40 nm MPP in transverse colorectal 
cryosections after intrarectal administration in DI water (20 mOsm); sodium-based tris 
buffers (TBS) with osmolalities of 20, 260, 350, 450, and 860 mOsm; 5% glycerol in DI 
water (600 mOsm); clinical iso-osmolal saline (260 mOsm); Fleet Naturals® (260 
mOsm); and regular Fleet® (2200 mOsm). Cell nuclei in transverse crysections were 
stained with DAPI. (B) Quantified surface coverage of MPP administered in various 
solutions on flattened mouse colorectal tissue. Images are representative of n ≥ 3 mice. 
White scale bars = 300 µm. Data are calculated as means ± SEM. *P < 0.05 as compared 






























Figure 4-2. The impact of potassium on the colorectal distribution of MPP. (A) 
Distribution of 40 nm MPP in transverse colorectal cryosections after intrarectal 
administration in DI water (20 mOsm), potassium phosphate buffer (K+, 150 mOsm), and 
sodium-based tris buffer (Na+, 150 mOsm). Cell nuclei in transverse crysections are 
stained with DAPI. Images are representative of n ≥ 3 mice. White scale bars = 300 µm. 
(B) Quantified surface coverage of MPP administered in potassium phosphate buffers 
with various osmolalities on mouse colorectal tissue. The images in (A) do not correspond 
with quantified surface coverage in (B), but are illustrative of the difference in distribution 
of MPP after administration in sodium and potassium based enemas. Data are calculated 







Figure 4-3. Distribution of TFV administered in sodium-based solutions with various 
osmolalities. Distribution in transverse colorectal cryosections after intrarectal 
administration of 1% TFV (1:10 TFV-FITC:TFV) in sodium-based tris buffers (450 and 
650 mOsm), DI water (20 mOsm), and iso-osmolal saline (260 mOsm). Cell nuclei are 
stained with DAPI. Images are representative of n ≥ 3 mice. White scale bars = 300 µm. 
 
  
650 mOsm 450 mOsm 





Figure 4-4. Distribution of TFV in SCS, SCS with only potassium, and SCS with 
only sodium ions matched to those in feces. Distribution in transverse colorectal 
cryosections after intrarectal administration of 1% TFV (1:10 TFV-FITC:TFV) in SCS, 
SCS without sodium (SCS, K+ only) and SCS without potassium (SCS, Na+ only). Cell 
nuclei in transverse cryosections are stained with DAPI. Images are representative of n ≥ 
3 mice. White scale bars = 300 µm. 
  





























Figure 4-5. Pharmacokinetic analysis of TFV in mouse colorectal tissue. The calculated 
amount of TFV present in mouse colorectal tissues is shown for up to 4 h after 
administration. 1% TFV was administered in the simulated colon solution (SCS) (150 
mOsm), isotonic TBS (450 mOsm), 5% glycerol gel (760 mOsm), and Fleet® enema (2200 
mOsm). Total amounts were calculated assuming tritiated and unmodified TFV entered the 
cells at the same rate Studies were performed in n ≥ 5 mice with highest and lowest value 
excluded to yield a total of n ≥ 3 sample points. Data is shown as mean ± SEM. *P < 0.05 





Figure 4-6. Acute toxicity of various enemas in the mouse colorectum. (A) 
Hemotoxylin and eosin (H&E) stained mouse colorectal tissue excised 10-15 min after 
intrarectal administration of DI water, simulated colon solution (SCS), or Fleet® enema. 
Red arrows indicate epithelial tissue that has separated from the tissue surface. Yellow 
scale bars = 100 µm. (B) Distribution of 40 nm (green) and 200 nm (red) MPP 
administered in a hypotonic solution 10 min after pretreatment with Fleet® enema. 
Yellow arrows indicate areas where MPP have penetrated into the damaged tissue. White 
scale bars = 100 µm. All images are representative of n ≥ 3 mice. 
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5. A NOVEL NON-MUCOADHESIVE DAPIVIRINE NANOCRYSTAL 
FORMULATION IN A NOVEL OSMOTIC THERMOSENSITIVE GEL FOR 
IMPROVED VAGINAL AND RECTAL PRE-EXPOSURE PROPHYLAXIS  
5.1 Introduction 
According to UNAIDS, More than 35 million people are currently living with HIV 
infection and ~3 million new infections occur every year 117. Unprotected vaginal and/or 
rectal intercourse are the two main sources of these new infections, with risks of 0.08-
0.3% per sexual act for vaginal transmission and 1.8% per sexual act for rectal 
transmission 228. Currently, neither preventative vaccines nor treatments have 
successfully eradicated the virus. The key strategy under investigation for ending the HIV 
epidemic is chemoprevention, or pre-exposure prophylaxis (PrEP) 121, 236-238. A promising 
initial step in PrEP development was the recent US FDA approval of Truvada®, an oral 
pill that combines two antiretroviral drugs, for use by high risk populations 122, 239. 
Truvada® and other systemic drug treatments, however, can have significant adverse side 
effects and some researchers have also voiced concerns that systemic drug exposure may 
lead to an increase in drug-resistant HIV strains 122, 239, 240. Topical PrEP provides a 
unique opportunity, as it can achieve therapeutic drug levels directly at potential sites of 
infection, while avoiding side effects from systemic PrEP.  
A number of topical delivery systems are currently under investigation for PrEP 
including vaginal rings, vaginal or rectal gels, and vaginal films 121, 122, 236, 241-243. Vaginal 
rings have the advantage of providing long-term drug release over several weeks, but 
they are less discrete, thus limiting their applicability in third world countries 242. Gels 




Africa 243-245. However, research has shown that the incomplete epithelial coverage 
provided by many gels is a major failure mode of vaginal microbicide products 246. In 
addition, rectally applied gels are unable to reach all internal surfaces potentially affected 
by HIV, since gels mostly remain in the rectosigmoid colon after rectal application 132, 134. 
In contrast, we have previously found that fluid-absorption inducing (hypotonic) vaginal 
and rectal aqueous fluid formulations cause hydrophilic drugs and non-mucoadhesive 
nanoparticles to evenly coat the vaginal and rectal epithelium 61, 79. In addition, Leyva et 
al have demonstrated that moderately fluid-absorption inducing enema formulations can 
reach all the way to the splenic flexure of the large intestine in a matter of 2 h 133. 
Aqueous formulations thus have the advantage of providing drug to the entire surface that 
may come in contact with HIV.  
Many of the antiretroviral drugs currently under investigation for PrEP are 
strongly hydrophobic and will poorly dissolve in an aqueous vehicle at therapeutic 
concentrations. Micronization is commonly used to help solubilize hydrophobic drugs in 
aqueous solutions. However, we have previously shown that large micron-sized (and 
down to 40 nm), hydrophobic particulates will become entrapped in the mucus barrier 15, 
79. Mucus is a highly viscoelastic hydrogel that coats the entire GI tract and effectively 
traps most pathogens and foreign particulates by hydrophobic and electrostatic 
interactions 8, 9. Nanoparticles that are larger than the mucus mesh spacing or are 
mucoadhesive do not provide uniform coverage of the colorectal or vaginal epithelium 
even when administered in strongly hypotonic aqueous vehicles (Chapter 4 and 5, 79). We 
have therefore designed nanoparticles that can slip through the mucus barrier, or are 




ensuring their size is smaller than the mucus mesh spacing 15. We have found that these 
mucus penetrating nanoparticles (MPP) can uniformly coat the colorectal and vaginal 
epithelium when administered in a hypotonic aqueous vehicle.     
Dapivirine (TMC120) is one of the strongly hydrophobic antiretroviral candidates 
currently under investigation for PrEP. We here investigat the development of a novel 
dapivirine mucus penetrating nanocrystal formulation (TMC120 NC) made from all 
generally regarded as safe (GRAS) materials as dual-compartment vaginal and rectal 
product, and test its application in a murine model. To ensure that the TMC120 NC 
formulation reaches all areas HIV can reach as delivered in human seminal plasma, we 
also investigate the properties of human seminal plasma as a delivery vehicle. Our results 
demonstrate that human seminal plasma is hypotonic to the mouse vagina and 
colorectum. We also show that TMC120 NC evenly coat the colorectal and vaginal 
epithelium, and are able to cover all areas that HIV can reach on the colorectal tissue. In 
addition, we illustrate a novel method to osmotically deliver free drug or nanoparticles in 
a thermosensitive gel (thermogel). Thermogels have recently received considerable 
attention due to their ability to form a gel only once administered, making their 
administration easier than that of regular gels 245, 247-249. However, when used in sub-
Saharan Africa, where outdoor temperatures are well above body temperature, these gels 
are rendered useless. For this reason, we developed a novel method to form thermogels: 
when solutions containing thermogel below critical gelling concentrations (CGC) are 
administered hypotonically, the fluid absorption will cause the materials to both evenly 
coat and concentrate to CGC or above at the epithelial surface. We determined that F127 




HIV, evenly coats the cervicovaginal and colorectal epithelium, and significantly 
improves the retention of both TMC120 NC and free drug surrogate in the cervicovaginal 
tract. Our investigations illustrate that a mucus penetrating TMC120 NC formulation and 
a novel osmotic thermogel can improve colorectal and vaginal drug delivery by providing 
uniform epithelial coverage and prolonging retention time.  
5.2 Materials and Methods 
5.2.1 Nanocrystal and MPP formulation and characterization 
Dapivirine nanocrystals (TMC120 NC) were fabricated by milling. Dapivirine was 
dissolved in methanol or acetone at 1% w/v and injected into a 1% F127 solution 
containing 10% polystyrene milling beads ranging from 0.4-0.6mm in diameter. 
Nanocrystals were covered and spun at 990 rpm for 4 days. Milling beads were removed 
and the resulting solution was filtered using a 0.22 µm filter. Fluorescein was conjugated 
to dapivirine to formulate fluorescent TMC120 NCs containing 10% w/w dapivirine-
fluorescein. FITC-TMC120 NCs were fabricated by the same method described above. 
MPP were formulated as previously described 176. Briefly, carboxylate-modified 
polystyrene beads (PS-COOH, Molecular Probes) were suspended in 200 mM borate 
buffer containing 5 kDa methoxy-polyethylene glycol-amine (mPEG-NH2), N-
Hydroxysulfosuccinimide (Sigma) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC, Invitrogen) to couple the amine group on the mPEG-NH2 with the carboxylic acid 
groups on the PS-COOH. Nanoparticles were washed and resuspended in deionized 
water.  
For both nanocrystals and MPP, size (z-average) and polydispersity index (PDI) 




scattering (90° scattering angle). Measurements were taken at 25°C according to 
instrument settings and are presented as average ± standard error of the mean (SEM). 
Final drug concentration in TMC120 NC solution was determined via a high pressure 
liquid chromatography (HPLC) 251. Images of TMC 120 NC were obtained using a 
Hitachi H7600 Transmission Electron Microscope (TEM). GFP labeled X4-HIV was 
graciously provided by the Siliciano lab at the Johns Hopkins University.  
5.2.2 Nanocrystal stability and release 
TMC120 NC were tested for long-term shelf life and stability in our previously 
developed SCS enema formulation. For long term shelf life, NC were lyophilized and 
stored at room temperature for up to 20 months. Size and PDI were measured at 2 weeks, 
1 month, 3 months, and 20 months. For stability in SCS enema, previously lyophilized 
NC were suspended in SCS and 20 µL were extracted for size and PDI measurements 
immediately after suspension and at 30 min, 1 h, 2 h, 4 h, 6 h, 24 h , and 48 h.  
TMC 120 NC release was determined by suspending 100 µL of nanocrystals in a 
sink of PBS containing 2% polysorbate 80 137, 251. Solution was removed at 0h, 1 h, and 2 
h and spun down at 13000 rcf to remove any undissolved nanocrystals. The solution was 
analyzed for TMC120 concentration using HPLC.  
5.2.3 Animal Model 
Female CF1 mice were used for both colorectal and vaginal distribution and retention 
experiments. For vaginal distribution, mice were selected for estrus phase, in which the 
mucus has been shown to be most similar to human cervicovaginal mucus 5, 64. For 
colorectal distribution, mice were starved for 24 h, and were given a 50 µL deionized 




For vaginal retention, animals were subcutaneously injected 2.5 mg of Depo Provera® 
(UpJohn) to induce a diestrus-like state 5. All experiments were approved by the Johns 
Hopkins Animal Care and Use Committee (ACUC). 
5.2.4 Distribution of nanoparticles, virus, nanocrystals, and osmotic thermogels on 
mouse vaginal and colorectal tissues 
For nanoparticle or virus distribution in the colorectum, 30-50 µL of vehicle (hypotonic 
pure water, human seminal plasma, or osmotic thermogel in form of 10% F127 in pure 
water) containing either 60 nm mucus penetrating nanoparticles, TMC120 NC, or X4-
HIV was administered intrarectally. For vaginal distribution of virus or nanoparticles, 5-
10 µL of vehicle (hypotonic pure water, human seminal plasma, or osmotic thermogel in 
form of 10% F127 in pure water) containing 120 nm mucus penetrating nanoparticles or 
labeled TMC120 NC was administered intravaginally. Tissues were excised after 5-10 
mins. For quantified colorectal distribution, tissues were cut open longitudinally, 
flattened between two glass slides, and 6 images were obtained along the tissue as 
previously described and quantified for fluorescence coverage using ImageJ 79. The 
percent surface coverage for each animal was averaged over the six images, and an 
overall average was calculated for n ≥ 3 mice. For qualitative distribution, tissues were 
excised, flash frozen in optimal cutting temperature compound (OCT), sliced into 6 µm 
slices using a Leica CM-3050-S cryostat, and cell nuclei were stained using ProLong 
Gold antifade reagent with DAPI (Invitrogen). All images were obtained using an 




5.2.5 Scanning electron microscopy (SEM) of colorectal tissue 
For determining the honey-comb pattern evident on flattened colorectal epithelial tissue, 
colorectal tissue was dried and prepared for scanning electron microscopy. Tissues were 
excised from healthy mice, fixed overnight, washed, and incubated in 1% w/v osmium 
(OsO4) for 1h. Tissues were again washed and incubated in 2% w/v aqueous uranyl 
acetate for 1h, and subsequently washed in 30% ethanol (EtOH), 50% EtOH, 70% EtOH, 
90% EtOH, 100% EtOH, 1:1 HMDS:100% EtOH and HMDS. Tissue bits were then 
dried in a dessicator overnight, mounted, and coated with silver for imaging using a 
LEO/Zeiss Field-emission SEM.  
5.2.6 HIV tracking on ex vivo tissue in the mouse colorectum and vagina pre and post 
osmotic gel administration 
To determine if HIV can diffuse in mouse vaginal and colorectal mucus, mice were either 
starved for 24 h for rectal application or selected for naturally cycling estrus for vaginal 
application. Mice were anesthetized with isoflurane, tissues were excised, and placed into 
custom made 1x0.5 cm wells, and 0.25 µL of mCherry-HIV solution was pipetted on top 
of the tissue. To determine if a thermogel was formed in the colorectum, mice were 
anesthetized using isoflurane and 50 µL of 10% F127 solution was administered 
intrarectally. Mice were sacrificed at 5 min and 1 h, colorectal tissues were excised and 
placed into custom-made 1 x 0.5 cm wells, and 0.25 µL of mCherry-HIV solution was 
pipetted on top of the tissue. To determine if a thermogel was formed in the 
cervicovaginal tract, mice were anesthetized using isoflurane, and 10 µL of 10% F127 
solution was administered intravaginally. Mice were sacrificed at 5 min and 1 h, vaginal 




mCherry-HIV solution was pipetted on top of the tissue. For all procedures, slides were 
covered with a cover slip, sealed with superglue and nanoparticle movement was imaged 
at 100x magnification over 20 s at 66.7 ms per frame using an EMCCD camera (Evolve 
512; Photometrics) on an inverted epifluorescence microscope. Nanoparticle movement 
was analyzed. Nanoparticle centroids were tracked for ≥ 30 frames using MATLAB to 
obtain trajectories and mean squared displacements (<MSD>) calculated as 〈∆𝑟2(𝜏)〉 =
[𝑥(𝑡 + 𝜏) − 𝑥(𝑡)]2 + [𝑦(𝑡 + 𝜏) − 𝑦(𝑡)]2 81, 178-181. Static and dynamic errors have 
previously been estimated to be below 20 nm, making them lower than the average 
nanoparticle displacement 179, 182. 
5.2.7 Retention of free drug and nanocrystals in the mouse vagina 
Fluorescein, a fluorescent free drug simulant, was dissolved at 1mg/mL in DI water, 18% 
F127, or 10% F127 solution with 1% v/v DMSO to ensure complete dissolution. 
Similarly TMC 120 NC were resolubilized in 1% or 10 % F127 solutions. Mice were 
anesthetized using isoflurane and restricted from grooming, which could alter retention 
results. 10 µL of fluorescein or TMC120 NC solutions were administered and mice were 
sacrificed immediately or after 24 h. Cervicovaginal tracts were excised and the 
fluorescence retained was analyzed using a  Xenogen IVIS spectrum optical imaging 
device (Caliper Life Sciences, Inc., Hopkinton, MA) at 1s exposure time. The average 
fluorescence normalized based on area was measured and percent retained was calculated 
based on the amount of fluorescence at 0 h 5. Statistical differences were calculated using 





5.3.1 TMC120 NCs stability and drug release 
The novel TMC120 NCs contained only dapivirine and 1% w/v F127, an FDA approved 
pluronic. Their z-average size was 200 ± 1 nm with a PDI of 0.122 ± 0.004 (Fig 5-1A & 
B). TMC120 NC size was stable for 48 h when suspended in a moderately hypotonic 
enema formulation (SCS) (Fig 5-1A), indicating their stability when exposed to ion-
containing solutions prior to administration. However, TMC 120 NCs exhibited an 
increase to a stable size of 280 ± 3 nm and PDI of 0.198 ± 0.01 (Fig 5-1 B) when left as 
dry powder at room temperature for 20 months, likely due to spontaneous crystal 
assembly since dapivirine naturally crystallizes (unpublished observation) 252. As shown 
in Figure 5-1C, TMC120 NCs also dissolved rapidly, with no crystals remaining after 2 
h. TEM images reveal smaller crystals <50 nm radius along with larger, more oval 
crystals with dimensions of  170 ± 10 nm by 125 ± 10 nm (Fig 5-1D). 
5.3.2 TMC120 NC distribution on mouse vaginal and colorectal tissue 
To ensure that the NC formulation is indeed mucus penetrating, we next assessed their 
distribution on the vaginal and colorectal epithelium. Fluorescein-labeled TMC120 NC 
evenly coated both the vaginal and colorectal epithelium when administered in a 
hypotonic solution, similar to model MPP (Fig 5-2) 5, 79. When developing an effective 
microbicide one must also consider what cells could come in contact with the pathogens. 
For this reason we investigated whether or not human seminal plasma, in which these 
pathogens are delivered, is hypotonic to the vaginal or colorectal tissue. Indeed human 
seminal plasma transports MPP to the murine vaginal and colorectal epithelial surfaces 




that human seminal plasma is hypotonic in nature to both the vaginal and colorectal 
epithelium.  
5.3.3 HIV distribution on mouse colorectal tissue 
When we then administered HIV in a hypotonic solution, as it would be in human 
seminal plasma, we found that it evenly coats the colorectal epithelial surface, covering 
>80% (Fig 5-3). To ensure that our nanocarriers are also able to reach all areas HIV 
reaches, we also determined the coverage of TMC120 NCs and model 60 nm MPP. Both 
of these nanocarriers have similar distribution to HIV (Fig 5-3A), with >80% of the 
epithelial surface coated (Fig 5-3B). In addition, the distribution of all three, MPP, 
TMC120 NCs, and HIV, results in a honeycomb pattern that we have identified as the 
colonic crypts (Fig 5-3C) 113, again indicating that there is no difference in distribution.  
5.3.4 TMC120 NC distribution in a thermogelling vehicle on colorectal and vaginal 
tissue 
We next investigated the distribution of the hypotonically delivered thermogel F127, 
which becomes a thermogel at 18% w/v (Fig 5-4A). When we administered 10% w/v 
F127, a concentration below CGC (Fig 5-4A), to the mouse colorectum or cervicovaginal 
tract, we found that a thick F127-mucus gel mixture forms (Fig 5-4B). In addition, when 
we administered TMC120 NC in 10% F127, they evenly coated both the vaginal and 
colorectal epithelium (Fig 5-4C).  
5.3.5 HIV diffusion on mouse colorectal and vaginal tissue with and without the presence 
of a thermogel 
In order to prove that a complete gel was indeed formed, we observed the movement of 




HIV is able to rapidly diffuse through mouse colorectal (Fig 5-5A) and vaginal (Fig 5-
5B) mucus, as indicated by the high <MSD> (Fig 5-5). HIV diffuses only 6-fold slower 
in vaginal and 70-fold slower in colorectal mucus compared to its diffusion in water. To 
illustrate that fluid absorption is occurring and causes F127 to concentrate and form a gel, 
we observed HIV movement on ex vivo colorectal and vaginal tissues 5 min and 1 h after 
administration of the F127. When we compared HIV movement in untreated mouse 
colorectal and vaginal mucus with movement in thermogel-treated tissues, HIV 
movement was similar to that in mucus 5 min after thermogel administration. In contrast, 
HIV movement was significantly inhibited 1 h after thermogel administration for both 
tissues (Fig 5-5), indicating that fluid absorption had sufficiently concentrated the gelling 
vehicle to trap HIV.  
5.3.6 Model drug and TMC120 NC retention with and without osmotic thermogel in the 
mouse vagina 
We investigated whether or not the osmotic thermogel improves the retention of both 
TMC120 NC and free drug. Here, we used fluorescein as surrogate drug molecule. When 
TMC120 NC or free fluorescein were administered in simple hypotonic formulations, 
their 24 h retention was 21 ± 3% for TMC120 NC (in 1% F127) and 7 ± 4% for free 
fluorescein (Fig 5-6). Administration in 10% F127, however, yielded 35 ± 2% TMC120 
NC and 23 ± 6% fluorescein retained over a 24 h period, a 70% increase for TMC120 NC 
and 230% increase for free fluorescein (Fig 5-6). In addition, the retention of free 
fluorescein delivered in osmotic thermogel was indistinguishable from its administration 




F127 (Fig 5-6B), indicating that the process of fluid absorption prior to gelling did not 
negatively affect drug retention.  
5.4 Discussion 
Formulating effective delivery vehicles for hydrophobic microbicides like TMC120 
presents a unique challenge. Unlike their hydrophilic counterparts, hydrophobic drugs 
will not simply dissolve in a hydrogel or douche formulation and thus require the addition 
of potentially harmful additives to ensure drug dissolution. Formulating TMC120 in a 
nanosuspension, as we have done in this work, eliminates the need for such additives, 
providing the basis for a versatile range of delivery vehicles. Many rectal and vaginal 
formulations have not been designed with epithelial health in mind 129, 253. In fact, many 
of the gels currently under investigation for vaginal or rectal microbicides have been 
highly strongly hypertonic, formulations which have recently been shown to cause 
significant epithelial toxicity 128, 129, 221, 230. Many commercially available lubricants and 
enemas are also hypertonic, and recent evidence has linked use of such products to an 
increased susceptibility to STIs 253. We have previously shown that hypotonic vehicles do 
not cause damage to the colorectal and vaginal epithelium. In addition, we have found 
that MPP are also non-toxic to the vagina. All materials used in our TMC120 NC 
formulation and in the osmotic thermogel are either GRAS or have been shown to be 
non-toxic, thus likely making the formulation non-toxic as well.  
 We have previously shown that uniform coating of mucosal surface can 
significantly improve protection against STIs as well as treatment of diseases including 
cystic fibrosis in inflammation 5-7. Prior methods to determine distribution have only 




et al (unpublished data) as well as our previously published work have illustrated that 
even longitudinal distribution will not account for distribution into all of the folds, or 
rugae, of the cervicovaginal tract 5, 246. The incomplete coverage of the vaginal epithelium 
is likely a major pitfall in microbicide design 246. Here, we demonstrated that TMC120 
NC administered hypotonically (with or without osmotic thermogel) evenly coat the 
vaginal epithelium. In addition, we have previously shown that mucus penetrating 
nanocrystals made from acyclovir monophosphate, an anti-herpes (HSV) drug, and 
coated with F127 improved protection against HSV infection compared to free drug 5. It 
was further concluded that this was due to the improved distribution and retention of the 
nanocarriers. The distribution of our TMC120 NC is similar to that of the model MPP 
used in these previous studies. Das Neves et al have also shown that dapivirine 
nanoparticles coated with PEG penetrate into vaginal tissue and improve drug retention 
compared to free dapivirine 136. Our results illustrate that using an osmotic thermogel can 
further extend the vaginal retention of drugs and drug-loaded nanoparticles. TMC120 NC 
delivered in an osmotic thermogel would therefore likely also lead to prolonged 
protection against HIV infection.  
In the colorectum, we found that the TMC120 NC penetrated deeply into the 
tissue. Similar results were obtained by das Neves et al who encapsulated TMC120 into 
polymeric nanoparticles coated with polyethylene glycol (PEG) 136, 137, 251. The TMC120 
nanoparticles were able to penetrate into vaginal and colorectal epithelial tissue 2 h after 
incubation with tissue 137. While this group saw significant uptake of their nanoparticles 
into the epithelium, it is uncertain whether or not this was due to the particles ability to be 




nanoparticles after removal from the physiological environment. In addition, the large 
amount of liquid that was incubated on only 1.8 cm2 of tissue likely significantly diluted 
the mucus layer 137. It is possible that this allowed nanoparticles to directly access the 
epithelial layer. While their methods may not be representative of the in vivo 
environment, their results still correlate with ours in that PEG coated nanoparticles can 
penetrate into vaginal and colorectal tissue. Recent results from Dezzutti et al has 
suggested that a thermogel formulation containing 1% w/v tenofovir, a hydrophilic 
antiretroviral drug, in 15% w/v F127 provided the best protection against HIV on human 
ex vivo biopsies, without causing any epithelial toxicity 248. Also, Wang et al have 
illustrated that using a F127-based thermogel will improve colorectal drug retention in a 
rabbit model 247. Their results demonstrate that both systemic and local drug levels are 
highest when using a thermogel administered in an enema compared to drug administered 
in a suppository or intravenously. These results indicate the promise of pluronic osmotic 
thermogels as PrEP drug delivery vehicle. 
 The importance of properly designing a drug delivery vehicle to reach the entire 
epithelial surface becomes more evident when we consider the vehicle in which HIV and 
other sexually transmitted infections are delivered. Most research has focused on 
understanding the mechanisms through which HIV infects cells in the vaginal and 
colorectal tissue and beyond 254, 255. However, the vehicle with which HIV reaches those 
cells has not been investigated thus far. Our data indicate that human semen serves as a 
hypotonic delivery vehicle for pathogens and particulates that are non-adhesive to mucus 
in both the vagina and the colorectum. Since HIV is able to diffuse in both colorectal and 




likely very similar. Indeed, we here showed that HIV administered in a hypotonic vehicle 
as it would be in human seminal plasma, distributes to the same areas that are reached by 
hypotonically delivered free drug, MPP, and MPP or free drug delivered in osmotic 
thermogel. Our results further support the hypothesis from Achilles et al that a 
conventional gel will not provide sufficient drug coverage of the epithelial tissue 246. The 
osmotic thermogel formulation discussed here uniformly coats the epithelial surfaces of 
the colorectum and vagina and would thus present an improved drug delivery vehicle for 
microbicide candidates.  
5.5 Conclusion 
We have developed a novel mucus penetrating TMC120 NC formulation that remains 
stable in solution over 48 h and rapidly releases drug when sufficiently diluted. The 
formulation evenly coats the murine vaginal and colorectal epithelial surfaces when 
administered hypotonically. In addition, we found that thermogels can be administered 
below CGC and will be concentrated to or above CGC when administered in a hypotonic, 
fluid-absorption inducing vehicle. The concentrated material will gel at the epithelial 
surface and can effectively trap HIV particles. In addition, TMC120 NC administered in 
the osmotic thermogel evenly coat the epithelial surface. We also determined that the 
addition of an osmotic thermogel to both free drug formulations and TMC120 NC leads 
to increased drug and nanocrystal retention in the cervicovaginal tract. Formulating 
dapivirine into mucus penetrating nanocrystals delivered in an osmotic thermogel has the 
potential to significantly improve drug delivery to the cervicovaginal tract and 







Figure 5-1. Size, stability, and drug release of TMC120 NC. (A) TMC120 NCs or free 
drug were suspended in PBS with 2% P80 and their drug release was determined over 
time via HPLC. TMC120 NC were lyophilized for size stability, and their size and PDI 
was assessed (B) after incubation in simulated colon fluid (saturated) or (C) after 
resuspension at various time points. (D) TEM image of TMC120 NC. Black scale bar 
represents 500 µm. Data are representative of n ≥ 3 measurements and values are 















































































Figure 5-2. Distribution of TMC120 NC in hypotonic solution and MPP in human 
seminal plasma after rectal or vaginal administration. Distribution of TMC120 NC 
with 1% F127 in DI water after rectal or vaginal administration, or 60 nm MPP after 
rectal or 100 nm PSPEG after vaginal administration in human seminal plasma. White 
scale bars represent 300 µm. Images are representative of n ≥ 3 mice. 
  



















































Figure 5-3. Distribution of TMC120 NCs, X4-HIV, and MPP on mouse colorectal 
crystal, and SEM of the colonic crypts. (A) Distribution of fluorescein-labeled 
TMC120 NC (200 nm), X4-HIV (160 nm), and MPP (60 nm) after rectal administration 
in a hypotonic fluid and (B) their quantification. (C) SEM image of the colonic tissue 
showing the colonic crypts that are outlined by the nanocarriers in (A). White scale bars 
represent 300 µm and black scale bar represents 20 µm. Images are representative of n ≥ 





Figure 5-4. Gelling behavior of F127 gels and distribution of TMC120 NC in osmotic 
thermogel after rectal or vaginal (estrus) administration. (A) gelling behavior of 10% 
and 18% F127 at 37 C ex vivo. (B) gelling behavior of 10% F127 (osmotic thermogel) 
after hypotonic administration to the mouse colorectum. (C) Distribution of fluorescein-
labeled TMC120 NCs after rectal or vaginal administration of 10% F127. White scale 













































































Figure 5-5. Transport properties of fluorescently labeled HIV after vaginal or rectal 
administration. Ensemble mean-squared displacement (<MSD>) with respect to time up 
to 3 s for (A) HIV moving in mouse colorectal mucus or on colorectal tissue 5 min or 1 h 
post administration of 10% F127 (thermogelling vehicle) and (B) HIV moving in mouse 
vaginal mucus or on vaginal tissue 5 min or 1 h post administration of 10% F127 
(thermogelling vehicle). W indicates the movement of a 100 nm nanoparticle in water. 











































Figure 5-6. Vaginal retention of TMC120 NCs or free fluoresceine after 24 h. 
Distribution of (A) fluorescein-labeled TMC120 NCs in 1% F127 or 10% F127 or (B) 
free fluorescein in DI H2O, 10% F127, or 18% F127 24 h after vaginal administration in 
1% (no gel) or 10% (hypotonic gel) F127. Values represent n ≥ 5 mice and are 
normalized to the average of the 0+ time point (0+h = 100%). *P < 0.05 compared to 1% 




6. FUTURE OUTLOOK 
In this thesis, I have shown the properties necessary to make nanoparticles rapidly diffuse 
through mouse GI mucus, including their size and surface charge; I have illustrated that 
these particles can be used as tools to assess whether or not fluid absorption is occurring, 
and I have developed a novel all GRAS MPP formulation for use in HIV prevention. 
There is, of course, much more to do.  
 A critical step to translating MPP to the clinic is to determine the properties 
necessary for nanoparticles to diffuse through human GI mucus. This will allow the 
proper design of drug-loaded nanocarriers that can provide uniform distribution on small 
and large intestinal tissues. Nanoparticles to develop include ones carrying poorly water 
soluble drugs and drugs with poor GI bioavailability in order to improve systemic 
delivery of these drugs, as well as ones carrying medications to treat local diseases such 
as IBD via both the rectal or oral routes. Moreover, the use of the microbicide-based 
nanocarrier (dapivirine MPP) for PrEP developed in Chapter 5 must be further 
investigated. This will include testing for toxicity and pharmacokinetics after colorectal 
administration and compared to free drug and current gel-based formulations. All 
developed nanoparticles, including the dapivirine MPPs, first need to be tested in murine 
models, but translation to a larger animal with GI tract function and transit times more 
similar to humans, such as pigs, will provide more insight into the improvements of MPP 
compared to MAP or free drug. 
 In addition to continuing the development of MPP for application in GI diseases 
and for improvement of oral-to-systemic drug delivery, developing proper delivery 




DREAM project, which focuses on developing and optimizing a microbicide-containing 
enema formulation as PrEP. The work in this project will translate the work from Chapter 
4 into humans. Another delivery vehicle for both drugs and drug-loaded nanoparticles are 
gels. The novel osmotic gelling method discussed in Chapter 5 only shows initial steps 
toward developing better gel vehicles for vaginal and colorectal drug delivery. I illustrate 
that both free drug and nanocarriers can benefit from an osmotic thermogel. We have also 
found that the osmotic thermogel can serve as a barrier to the diffusion of infectious 
agents including HIV and HSV, though to this point the formulations tested so far have 
not increased protection from HSV infection vaginally. Further investigation for the use 
of an osmotic thermogel as a physical barrier against infections is still needed. The idea 
of using osmosis to form a gel right at the epithelial surface is not only limited to 
thermogels. My findings can easily be translated to gels including the 
hydroxyethylcellulose (HEC) based gels used in vaginal products. New gel products, 
especially dual-compartment gels, that provide uniform coverage of the vaginal and rectal 
epithelium may be particularly useful for prevention of STIs as well as for treatment of 
local vaginal and colorectal infections.  




I. APPENDIX I – THE MUCOADHESIVITY PARADOX REVISITED: 
NANOPARTICLES DENSELY COATED WITH HIGH MOLECULAR 
WEIGHT POLYETHYLENE GLYCOL (PEG) ARE NOT MUCOADHESIVE 
AND RAPIDLY PENETRATE HUMAN MUCUS 
I.1 Main Text 
Mucus, the first line of defense on all mucosal surfaces, is a sticky, viscoelastic gel that 
effectively traps many pathogens, preventing them from reaching and infecting the 
underlying tissue. The trapping mechanisms (mucoadhesion, sieving, and unstirred 
adherent mucus layers) can significantly interfere with drug delivery to epithelial surfaces 
by preventing particulates from reaching the epithelial surface if they are larger than the 
mucus mesh or if they adhere to the mucus mesh 5, 8, 9, 15, 19.  Most nanoparticles designed 
for mucosal drug delivery are designed to be mucoadhesive, but we have shown that such 
particles provide incomplete distribution on vaginal, lung, and colorectal tissues 5, 7, 61, 79, 
whereas nanoparticles densely coated with polyethylene glycol (PEG), are able to 
penetrate the mucus barrier to reach and evenly coat the entire epithelial surface 5, 7, 15, 79. 
In addition, mucus penetrating nanoparticles (MPP) are retained for longer periods of 
time in the cervicovaginal and respiratory tracts compared to mucaodhesive particulates 5, 
7, indicating that MPP are more suitable for distributing drug to the entire epithelial 
surface and prolonging drug retention 5, 7, 79. 
 Research has shown that adding PEG to hydrogels and hydrogel microparticles 
causes their surfaces adhere to mucus 72-74, 256-259. PEG was shown to act as a kind of 
mucoadhesive “glue” that could entangle with mucin fibers 73, 257 or form hydrogen bonds 




hypothesized that dense coatings of lower molecular weight (MW) PEG would not 
entangle with mucins and the hydrophilic and uncharged nature of PEG would allow 
nanoparticles to avoid adhesion 15. Indeed, we showed that nanoparticles with a high 
surface density of low MW PEG (2 kDa and 5 kDa) rapidly diffused in human 
cervicovaginal mucus (hCVM) 15, 67, 68, 76. We found that dense surface coverage by 
neutrally-charged PEG produced nanoparticles with a near-neutral surface charge (ζ-
potential) that have a “mucoinert” surface that is non-mucoadhesive and non-
inflammatory 5, 7, 261. In contrast, nanoparticles with positively charged surfaces, and/or 
uncoated hydrophobic surfaces, were adhesive to mucus and also inflammatory 5, 15. 
When we attached PEG with higher MW, 10 kDa, the particles became mucoadhesive, 
which we expected may be due to PEG entanglement with the mucus gel and/or 
insufficient PEG coverage on the nanoparticle surface 75. We have recently optimized 
reaction conditions that can achieve higher PEG surface densities on nanoparticle 
surfaces as compared to our previous methods 78, 176. Here we report that by using these 
new methods we can increase surface density of higher MW PEG (up to 40 kDa), and 
nanoparticles coated with PEG up to 40 kDa can rapidly penetrate hCVM.  
 To compare directly our prior and current PEGylation methods, we coated 
carboxylate-modified polystyrene (PS) nanoparticles with 10 kDa PEG using two 
different buffers: pH 7.4 200 mM borate buffer 176, and pH 6, 50 mM 2-(N-
morpholino)ethanesulfonic acid (MES) buffer 15. We found that PS coated with 10 kDa 
PEG using the borate method (PS-PEGborate) were able to rapidly diffuse through hCVM. 
The ensemble-averaged mean squared displacement (<MSD>) of PS-PEGborate (260 ± 7 




kDa PEG using the MES method (PS-PEGMES ; 220 ± 10 nm; -12 ± 0.4 mV; Fig I-1A, 
Table I-1). The <MSD> and the logarithmic distribution of individual MSD values for 
PS-PEGMES were similar to those of mucoadhesive, unmodified PS (180 ± 1 nm; -59 ± 2 
mV) in hCVM (Fig I-1A, B) as we reported previously 75. Nanoparticle trajectories 
representing 3 s of movement in hCVM further emphasize the difference in transport in 
hCVM, as PS-PEGborate moved in a diffusive random walk, while PS and PS-PEGMES 
remained immobilized, moving less than their diameter. In addition, the PS-PEGborate 
moved only 11-fold slower than in water (Table I-1), whereas PS-PEGMES were >10,000-
fold slowed in hCVM compared to their theoretical diffusion rates in water (Table I-1). 
To further understand the difference between the diffusion abilities of PS-PEGborate vs PS-
PEGMES, we determined the PEG density on PS-PEG nanoparticles. We previously used a 
fluorimetric method for determining PEG density, where we conjugated fluorescent dyes 
to the free carboxylic acid groups on the PS beads after coating them with PEG 75. When 
using this method, PEG density on the surface of PS-PEGMES coated with 5 kDa PEG 
was slightly higher than that of PS-PEGMES coated with 10 kDa PEG 
75. These results 
were confirmed with our more sensitive, previously published NMR method for 
measuring PEG surface density 78, 176: PS coated with 10 kDa PEG using the MES 
method seemed to have slightly lower PEG densities than PS coated with 5 kDa PEG 
using the borate method. In addition, we found that PS-PEGborate coated with 10 kDa PEG 
also had slightly higher PEG density, calculated as unconstrained area covered by PEG 
chains/total surface area (Γ/SA), namely 1.3 ± 0.1 for PS-PEGMES compared to 1.5 ± 0.1 
for PS-PEGborate (Table I-1). The Γ/SA values correspond to 2.9 ± 0.3 PEG chains per 100 




surface density (Γ/SA) < 1 will lead PEG to be in mushroom conformation, in which 
neighboring PEG chains do not overlap, which may leave some of the hydrophobic 
nanoparticle core exposed and allow the PEG chains to interpenetrate with mucin or 
extracellular matrix fibers 71, 73, 74. When Γ/SA > 1, PEG chains begin form a brush 
regime, where neighboring PEG chains are able to overlap, the hydrophobic nanoparticle 
core is likely no longer exposed and PEG chains are more constrained from interacting 
with surrounding tissue fibers 262. We have previously shown that PS-PEG with Γ/SA < 
1.7 were unable to penetrate brain tissue 176, indicating that a PEG density threshold 
exists for nanoparticles to be non-adhesive to the brain parenchyma. Similarly, it seems 
that a PEG density threshold must be exceeded to make nanoparticles mucus penetrating 
since a small increase in PEG density allowed the PS-PEGborate rapidly diffuse through 
hCVM.  
 Using the optimized method to coat PS nanoparticles with PEG, we tested the 
effect of PEG MW on nanoparticle diffusion in mucus. We found that 200 nm PS coated 
with up to 40 kDa PEG (with sizes ranging from 230 – 300 nm, refer to Table I-1) were 
able to rapidly penetrate hCVM, as indicated by the high <MSD> (Fig I-2A). The 
logarithmic MSD distribution of these nanoparticles in hCVM showed a high fraction of 
moving nanoparticles for all MWs (Fig 2b). In addition, the 3 s trajectories indicated a 
random walk, in stark contrast to the mucoadhesive PS that remain in place (Fig I-2C). 
All non-mucoadhesive nanoparticles also had high PEG density (Table I-1). It is evident 
that the number of PEG/ 100 nm2 decreases as PEG MW increases, as the # PEG/100 
nm2 was 7.1 ± 0.4 and 1 ± 0.1 for 5 kDa and 40 kDa PEG, respectively (Table I-1). The 




occupied by one unconstrained 5 kDa PEG chain is ~23 nm2 and increases 8-fold to ~180 
nm2 for unconstrained 40 kDa PEG molecules. Thus a smaller total number of PEG 
chains is needed to cover the surface of the particles completely as PEG MW increases.  
Similar to our results for 200 nm PS-PEGborate (ranging between 230 – 300 nm, 
Table 1), 100 nm PS-PEGborate (ranging between 110 – 170 nm, Table I-1) coated with 5 
kDa, 10 kDa, 20 kDa, and 40 kDa all possessed high PEG density (Γ/SA > 2 176, Table I-
1) and were able to rapidly diffuse through hCVM. The high <MSD> of each of these 
particle types, and the large fraction of diffusive nanoparticles (Fib 3a and b), suggest that 
PEG MW (ranging from 2 – 40 kDa) does not directly affect the ability of nanoparticles 
to penetrate hCVM. Particle trajectories indicate a random walk, in stark contrast to the 
immobilized PS (Fig 3c). Both 100 nm and 200 nm PS-PEG coated with 5kDa - 40 kDa 
MW were all < 20 fold slowed in hCVM compared to their diffusion in water (Table I-1).  
Higher MW PEG has been previously associated with increases in mucoadhesion 
72-74, 257, 259, 260, 263, 264. Peppas et al. have suggested that tethering PEG to different 
polymers and gels makes them more mucoadhesive by providing chains that are capable 
of entangling with and interpenetrating into the mucus gel 73, 257, 260. They have reported 
that PEG will, over time, diffuse into the mucin network, due to its hydrophilic nature, 
where it can undergo hydrogen bonding with the polysaccharide groups found on mucins, 
and thus provide an anchor for the material it is attached to 260 In addition, DeAscentiis et 
al determined that for poly(hydroxyethyl methylcellulose) (pHEMA) microparticles, 
coatings with 1 kDa PEG actually led to increased mucoadhesion compared to 100 kDa 
PEG 256. They hypothesize that because 100 kDa PEG chains could theoretically form 




interpenetration by 100 kDa into the mucin gel and thus less mucoadhesion 256. These 
results correspond with our previous findings that 10 kDa PEG leads nanoparticles to 
adhere to mucus 75. However, our findings here illustrate that when a dense enough PEG 
layer is formed on a nanoparticle surface, the nanoparticles will no longer adhere to 
mucus. The increased number of PEG molecules present on the nanoparticle surface 
likely sterically hindered PEG molecules from interacting with mucus, and thus kept 
them from interpenetrating into or forming hydrogen bonds with the mucins. In addition, 
it is not surprising that larger MW PEG will more effectively prevent nanoparticles from 
interacting with biological surfaces, as He et al. have reported that using 20 kDa PEG can 
improve systemic nanoparticle immunogenicity and circulation times compared to 
nanoparticles coated 5 kDa PEG due to better stealth properties 265.  
 We have previously seen indications that mucus penetrating nanoparticles (MPP) 
more effectively improve treatment and prevention of diseases at mucosal sites, including 
preventing herpes (HSV) infection in the CV tract and asthmatic lung inflammation as 
well as treating diseases like cervical cancer and cystic fibrosis 5, 7, 266, 267. Using PEG 
with MW ≤ 40 kDa allows for additional flexibility in formulating drugs into 
nanoparticles, and thus a more versatile range of drug-loaded MPP is possible. We have 
also observed that the use of MPP in a vehicle that causes fluid uptake by the epithelium 
improves distribution on vaginal and colorectal tissue compared to mucoadhesive 
particles 5, 61, 79. Here we have investigated whether nanoparticles coated with higher MW 
PEG that diffuse in hCVM can also improve distribution in the cervicovaginal tract and 
colorectum compared to mucoadhesive nanoparticles. We administered 5 µL of 




which the mucosa and mucus layer are most similar to those in the human vagina and 
hCVM, and 20 L of nanoparticle solutions to the colorectum of mice that had been 
starved for 24 h 5. Nanoparticles were administered with hypotonic solutions that cause 
rapid fluid uptake from the vaginal and colorectal lumen 61. We found that mucoadhesive 
PS remained in the lumen (Fig I-4), but non-mucoadhesive 40 nm (colorectum) and 100 
nm (vagina) PS-PEGborate with PEG MW ≤ 40 kDa were transported rapidly to the 
epithelial surface and evenly coated virtually the entire mouse colorectal and vaginal 
epithelium. This demonstrated that PS-PEG that diffuse rapidly in hCVM ex vivo mucus 
are also advectively transported through mucus in vivo by the flow of water toward the 
epithelium.  
I.2 Materials and Methods 
I.2.1 Nanoparticle formulation 
PEG-coated nanoparticles were synthesized using the two methods previously described. 
For the “MES method”, excess methoxy-polyethylene glycol (mPEG)-amine (10 kDa) 
was dissolved in 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer at pH 6 
(Sigma). 200 nm carboxylate-modified polystyrene (PS) beads (Molecular Probes) were 
added to the MES/PEG mix and sonicated. 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC, Sigma) and N-Hydroxysulfosuccinimide (NHS, Sigma) were added 
to make a ratio of 0.1:1:1:1 COOH:PEG:EDC:NHS. The mixture was incubated at 37°C 
overnight, and then the nanoparticles were washed twice with DI water. For the borate 
method, 40 nm, 100 nm, or 200 nm carboxylate-modified PS beads (Molecular Probes) 
were coated with polyethylene glycol (PEG) with molecular weight of 5 kDa, 10 kDa, 20 




7.4) and respective methoxy-PEG-amine was added in excess. Excess amounts of NHS 
and EDC were added. The nanoparticle mixtures were incubated at room temperature 
overnight and subsequently washed twice with DI water. Nanoparticles were suspended 
in a 10 mM NaCl solution, and characterized with dynamic light scattering (DLS) for size 
and laser Doppler anemometry for ζ-potential measurements using a Zetasizer Nano 
ZS90 (Malvern Instruments). DLS was performed at 90° scattering angle and all 
measurements were taken at 25°C, in accordance with the instrument settings. ζ-potential 
close to 0 mV indicate PEGylation was complete 15, 176.  
I.2.2 PEG surface density measurements 
PEG density was calculated as previously described 78, 176. Briefly, nanoparticles were 
fully dissolved in deuterated chloroform (CDCl3, Sigma), trifluoroacetic acid-d (TFAd, 
Sigma), and a known concentration of Tetramethylsilane (TMS, 1% w/v). H-NMR 
spectra were obtained using a Bruker REM400 at 400 mHz. PEG density, or Γ/SA, was 
calculated from the integral of the PEG peak (3.6 ppm) and the internal standard TMS 
peak (0 ppm). To calculate the area occupied by the PEG chains on each particle, a 
random walk statistics model was used to find the area occupied by PEG of a certain 
length. These calculations yield a sphere with diameter d = 0.76 (mb)
0.5 where mb is the 
molecular weight of the PEG in question, yielding an area occupied by PEG of A = 
π(d/2)2 70. The areas occupied were then used to calculate the number of PEG chains per 
100 nm2 and area occupied by PEG chains/total particle surface area (Γ/SA). PEG 5 kDa 
was used for calibrating PEG concentration in solution. For PEG surface density 
calculations, it was assumed that the nanoparticles' surfaces are smooth and their 




I.2.3 Multiple particle tracking in human cervicovaginal mucus 
Human cervicovaginal mucus (CVM) samples were obtained by self-collection using a 
menstrual collection device as previously described 15, 268 and approved by the 
Institutional Review Board of the Johns Hopkins Medical Institution. Up to 2 µL of 
particle solution (0.02-0.08% w/v) was added to a volume of 30 µL hCVM in a custom 
made well. Wells were sealed with a coverslip that was affixed with superglue. Movies 
were obtained with a 100x/1.46 NA oil-immersion objective via an EMCCD camera 
(Evolve 512; Photometrics) as part of an inverted epifluorescence microscope setup 
(Zeiss Axio Observer). Movies were 20 s in time and had a 66.7 ms temporal resolution. 
Nanoparticle trajectories and mean squared displacements (MSD) were obtained using 
MATLAB 67 with a minimum of 30 frames tracked for each particle, and MSD calculated 
as  〈∆𝑟2(𝜏)〉 = [𝑥(𝑡 + 𝜏) − 𝑥(𝑡)]2 + [𝑦(𝑡 + 𝜏) − 𝑦(𝑡)]2 15, 81, 180. Our prior work has 
indicated that static error can be estimated to be below 20 nm, much smaller than the 
average particle displacement 7, 81. 
I.2.4 Nanoparticle distribution in the mouse vagina and colorectum 
Female CF-1 mice 6-8 weeks old were housed in a reverse light cycle facility (12 h light, 
12 h dark) for one week to allow acclimatization. For vaginal distribution, mice were 
selected for naturally cycling estrus by visual appearance of their introitus as previously 
described 269, as this phase makes the vagina most similar to the human vagina 270, 271, and 
gives their mucus similar barrier properties to human CVM 64. For colorectal distribution, 
mice were starved for 24 h, as this decreases the number and hardness of the pellets 79. 
Mice were anesthetized using isoflurane, and 5 µL (vaginally) or 20 µL (rectally) of 




Mice were sacrificed after 5-10 min (dissection speed) and tissues were excised, flash 
frozen in Tissue-Tek O.C.T. Compound, and sectioned into 6 µm slices along the entire 
length of the vagina and colorectum with a Leica CM-3050-S cryostat. Slices were fixed 
with 10% formalin and stained using ProLong Gold antifade ® reagent with DAPI to 
stain nuclei and retain particle fluorescence. Images were obtained using the inverted 
epifluorescence microscope setup (Zeiss Axio Observer). All experiments were approved 








*based on literature 176 
 
  
Table I-1. Surface, size, and diffusional properties of PS and PS-PEG. Size, ζ-
potential, PEG surface density (area covered by PEG/total surface area, or Γ/SA), and the 
comparison of the ensemble averaged MSD in mucus (<MSD>) to the theoretical MSD 
of similarly sized particles in water (MSDw) (indicating how much slower the 
nanoparticles move in mucus, MSDw/<MSD>), of 100 and 200 nm PS and PS-PEG 
prepared by various methods. Unless otherwise indicated, PS-PEG are prepared via the 



















PS - 90 ± 1 -51 ± 1.6 0 0 >10,000 
PS-
PEG 
5 110 ± 2 
-3.1 ± 
0.3 
>2* ~9* 10 
10 120 ± 7 
-0.5 ± 
0.1 
2.0 ± 0.1 4.4 ± 0.2 18 
20 130 ± 4 
-0.4 ± 
0.1 
3.3 ± 0.1 3.3 ± 0.1 6 
40 170 ± 8 -1 ± 0.1 2.1 ± 0.2 1.2 ± 0.1 20 
200 
PS - 180 ± 1 -59 ± 2 0 0 >10,000 
PS-
PEG 
5 230 ± 5 
-1.6 ± 
0.1 
1.6 ± 0.1 7.1 ± 0.4 9 
10 260 ± 7 
-0.7 ± 
0.5 
1.5 ± 0.1 3.3 ± 0.1 11 
10 
(MES) 
220 ± 10 -12 ± 0.4 1.3 ± 0.1 2.9 ± 0.3 >10,000 
20 270 ± 7 -2 ± 0.7 1.7 ± 0.1 1.9 ± 0.2 10 









































































Figure I-1. Transport in hCVM of 200 nm PS and PS coated with 10 kDa PEG using 
borate or MES method. (A) Ensemble mean-squared displacement (<MSD>) with 
respect to time up to 3 s for PS and PS-PEG. (B) Distributions of the logarithms of 
individual particle MSD of PS and PS-PEG at a time scale of 1 s. (C) Representative 













































PS-PEG40 kDa  






































PS with 5 kDa -  40 kDa PEG
PS
Figure I-2. Transport in hCVM of 200nm PS and PS-PEG with varying MW PEG. 
(A) Ensemble averaged mean-squared displacement (<MSD>) as a function of time up to 
3 s for PS and PS-PEGborate coated with 5 kDa, 10 kDa, 20 kDa, and 40 kDa PEG. (B) 
Distributions of the logarithms of individual particle MSD of PS and PS-PEG at a time 
scale of 1 s. (C) Representative trajectories for 3 s of motion of PS and PS-PEG. Data are 
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PS with 5 kDa -  40 kDa PEG
PS
Figure I-3. Transport in hCVM of 100 nm PS and PS-PEG with varying MW PEG. 
(A) Ensemble averaged mean-squared displacement (<MSD>) as a function of time for 
PS and PS-PEGborate coated with 5 kDa, 10 kDa, 20 kDa, and 40 kDa PEG, including the 
theoretical MSD of 120 nm particles in water (W). (B) Distributions of the logarithms of 
individual particle MSD of PS and PS-PEG at a time scale of 1 s. (C) Representative 





Figure I-4. Distribution of PS and PS-PEG with varying MW PEG in the mouse 
vagina and colorectum immediately after administration. Fluorescent images (10x 
magnification) of transverse vaginal and colorectal cryosections after administration of 
solutions containing either PS, or PS-PEGborate coated with various MW PEG (5 kDa, 10 
kDa, 20 kDa, 40 kDa). Cell nuclei are stained blue with DAPI and scale bars represent 









II. APPENDIX II – HYDROXYL-FUNCTIONAL PAMAM DENDRIMERS 
EVENLY COAT MUCOSAL SURFACES AND HAVE HIGH CELLULAR 
UPTAKE IN THE COLORECTUM  
II.1 Introduction 
Nanoscale drug delivery systems may overcome many barriers faces by drugs, facilitate 
localized drug targeting and thus improve therapeutic efficacy 272-274. Nanoparticles are 
particularly versatile in as they can provide controlled and sustained release, protect drug 
from enzymatic and acidic degradation in the body, allow surface conjugation of targeting 
moieties and improve tissue penetration and cellular transport206, 207, 274-278. In fact, several 
nanotherapeutics have been approved by the US Food and Drug Administration for 
treatment of a variety of diseases including cancer (e.g. ovarian cancer and myeloma) and 
infectious diseases (e.g. hepatitis C, fungal infections) 279. Considerable interest lies in the 
development of local drug delivery to mucosal surfaces including the gastrointestinal (GI), 
cervicovaginal (CV), and respiratory tracts,  since research has shown that local treatment 
of mucosal diseases improves drug concentrations in the affected tissues 280-284 while 
preventing undesired systemic effects 206, 207, 280, 285. However, nanocarriers face one main 
obstacle from reaching their target cells at the mucosal sites: the mucus barrier.  
Mucus is a highly viscoelastic substance that effectively traps many pathogens and 
particulate matter, and lubricates the surface in order to protect the underlying epithelial 
layer. Mucin fibers make up most of the gel structure and are highly entangled, forming a 
mesh that allows only molecules smaller than the average mesh spacing to pass through. 
In addition, mucins have highly glycosylated, negatively charged regions and regions of 




interactions 8, 9. Mucus is rapidly cleared, on the order of hours in the CV, GI and 
respiratory tracts, clearing any trapped particulates or pathogens with it 8, 9. Current 
strategies for local delivery of nanocarriers to the mucosal surfaces focus on increasing cell 
uptake via cellular targeting mechanisms 286, which often ignore the mucus barrier that 
must be traversed in order to reach the underlying cells. Mucoadhesion strategies have also 
been suggested to improve mucosal drug delivery; however, mucoadhesion can lead to 
incomplete coating of the epithelial surface and thus rapid clearance from mucosal 
surfaces, which can make treatments less effective 261, 287. In addition, it may not lead to 
the cellular uptake, which is a key requirement for the treatment of many mucosal diseases 
286.  
We have previously shown that a dense layer of polyethylene glycol (PEG) makes 
nanoparticles non-mucoadhesive, allowing them to slip through the mucus if they are 
smaller than the mucus mesh spacing, and thus reach the underlying epithelial layer 7, 15, 
287, 288. In addition, we have shown that these nanoparticles are able to take advantage of 
advective fluid flow induced by hypotonic liquids that allow the nanoparticles to be 
dragged through mucus, and thus rapidly form an even coating on epithelial surfaces 61. 
Because of the ability to evade mucosal clearance, mucus penetrating particles (MPP) have 
improved efficacy in treatment and prevention of diseases, including cervical cancer, 
herpes simplex virus infection, and cystic fibrosis 261, 287, 289. While MPP bring drug more 
efficiently to the epithelium, the PEG coating can shield nanoparticles from cellular 
interaction and uptake.  
Some classes of smaller nanocarriers, such as dendrimers, are actively taken up by 




promising candidates for imaging and targeted drug/gene delivery, for diverse indications 
including cancer and central nervous system disorders 293-301. The small size, branching 
architecture, and high density of tailorable surface functional groups may provide 
significant advantages for organ and cell-specific transport 302. Polyamidoamide 
(PAMAM) dendrimers are widely studied due to their commercial availability. Recent 
studies have shown that PAMAM dendrimer size can have a significant impact on 
biodistribution and blood circulation time 303-305.  Many studies have been conducted on 
their in vitro cellular uptake by mucosal epithelial cells 290-292, 306. These have indicated that 
dendrimers are well-suited for drug delivery to the mucosal surfaces, but only few have 
been translated into in vivo studies. Recent findings suggest that, with appropriate surface 
functionality, dendrimers help improve both oral and pulmonary drug delivery. Dendrimer-
drug conjugates improve transport, increase drug solubility, and provide sustained release 
303, 307-311; however, none of these studies have directly correlated surface functionality to 
in vivo distribution and cellular uptake at the mucosal surfaces. Here, we investigate for 
the first time the interaction of PAMAM dendrimers with mucus, and the effects of surface 
functionality on the in vivo dendrimer distribution and cellular uptake at mucosal surfaces, 
with particular focus on the gastrointestinal tract.  
II.2 Materials and Methods 
II.2.1 Dendrimer conjugates 
Ethylene diamine core polyamido amide (PAMAM) dendrimers (generation 4 hydroxyl, 
D-OH, and amine-terminated, D-NH2, as well as generation 3.5 carboxyl terminated, D-
COOH) were obtained (Dendritech, Inc.) and labeled with either fluorescein isothiocyanate 




NH2) as previously described 
302, 306, 312. These conjugates have 1-2 molecules of the 
fluorescent agent per dendrimer, and fluorophore and dendrimer are linked via a stable 
amide bond that has been previously shown to resist hydrolysis 313. The conjugates are 
highly soluble in water, have been shown to be stable in PBS and plasma for up to 24 h at 
37C, and can be extracted intact from tissue 312, 313. 
II.2.2 Animal models 
Female CF-1 mice 6-8 weeks old were obtained (Harlan) and housed for 1 week for 
acclimatization. For colorectal distribution, mice were starved for 24 h prior to 
administration of dendrimer. For vaginal distribution, naturally cycling mice were selected 
to be in estrus phase, which we have previously shown to be most similar to the human 
epithelial thickness and the mucus is most similar to human CV mucus 64, 287. For all routes 
of administration, mice were anesthetized using isoflurane. Experiments were approved by 
the Animal Care and Use Committee of the Johns Hopkins University. 
Distribution of dendrimers on colorectal, vaginal and lung surfaces 
For colorectal distribution, 20 µL of 1 mg/mL FITC-labeled dendrimer solution (D-OH, 
D-COOH, or D-NH2) was administered intrarectally using a Wiretrol (Drummond). For 
vaginal distribution, 5 µL of 1 mg/mL Cy5-labeled dendrimer (D-OH, D-COOH, or D-
NH2) solution was administered. Tissues were excised immediately (with dissection times 
between 5-10 min), flash frozen in optimal cutting temperature compound (OCT), and cut 
into 6 µm thick sections. For distribution in the trachea, 50 µL 1 mg/mL Cy5-labeled 
dendrimer solution (D-OH, D-COOH, or D-NH2) was administered intranasally. Lungs 
were excised after 30 min, flash frozen in OCT, and cut into 10 µm thick sections. All 




with ProLong Gold antifade reagent with DAPI (Invitrogen). Tissues were imaged using 
an inverted epifluorescent microscope (Zeiss Axio Observer). 
For semi-quantitative distribution, mice were given 200 µL deionized (DI) water 
enemas prior to administration of 50 µL 1 mg/mL of respective FITC-labeled dendrimer 
(D-OH, D-COOH, or D-NH2) solutions. Mice were sacrificed after 5-10 min (dissection 
time), and tissues were excised, longitudinally sliced open, and flattened between two glass 
slides. Tissues were then imaged using an inverted epifluorescent microscope (Zeiss Axio 
Observer). To ensure fluorescence levels were above autofluorescence, control tissues 
were imaged prior to tissues containing dendrimers. For quantification, 6 images were 
taken per tissue. Images were threshholded, and analyzed for fluorescence coverage using 
ImageJ as previously described 287. Data is reported as average ± SEM, and corresponds to 
n ≥ 3 mice.  
II.2.3 Methods for determining dendrimer cell uptake in the colorectum 
The initial cell extraction method was adapted from Boothe et al 314. Mice were 
anesthetized using avertin and 50 µL of 1 mg/mL FITC-labeled dendrimer solution (D-OH 
or D-NH2) was administered intrarectally. Tissues were excised after 2 h, sliced open 
longitudinally, cut into 1cm pieces, and placed into a 1.5 mL tube. A solution of DMEM 
with 10% FBS and 4 mg/mL was added and tissues were incubated at 4°C over night. 
Tissues were transferred into a 1:1 mixture of 0.05% trypsin-EDTA and Versene and 
incubated at room temperature for 3 h. The reaction was stopped by adding DMEM/10% 
FBS and tissue pieces were removed. Cells remaining in the tubes were spun down and 
half of control tissue cells were incubated with SYTO® green fluorescent nucleic acid stain 




and then were washed with cold PBS and filtered through a 60 µm cell strainer. % 
fluorescent cells were obtained via flow cytometry using an Accuri C6 flow cytometer 
(BD).  
For cell uptake studies using only the mucosa, following a method adapted from 
Bjerknes et al, mice were anesthetized using avertin and 30 µL of 2 mg/mL FITC-labeled 
dendrimer solution (D-OH, D-COOH, or D-NH2) was administered intrarectally 
315. 
Tissues were excised after 30 min or 4 h, and inverted onto a glass wiretrol. Tissues were 
incubated in 30 mM EDTA in HBSS with 4 mg/mL dispase at 37°C under rotation for 1 h. 
Tissues were removed, cell sheets spun down and resuspended with DMEM/10% FBS and 
4 mg/mL dispase at room temperature for 30 min. Cells were spun down and filtered 
through a cell strainer. Positive controls were incubated with 5 µL SYTO ® green 
fluorescent nucleic acid stain (Molecular Probes) and all samples were subsequently 
washed with cold PBS. % fluorescent cells were obtained via flow cytometry using an 
Accuri C6 flow cytometer (BD).  
II.2.4 Semi-quantitative method for determining dendrimer retention in the colorectum 
Dendrimer retention was assessed based on fluorescence retained 2 h after administration. 
Mice were anesthetized using averting, and 50 µL of 2 mg/mL D-OH, D-COOH, or D-
NH2 were administered to the colorectum. Mice were allowed to wake up, sacrificied after 
2h, and the entire colorectum was excised and subsequently washed with PBS to remove 
any luminal contents. Tissues were then lyophilized, crushed, and incubated in methanol 
(D-OH and D-COOH) or phosphate buffered saline (PBS, D-NH2) to extract the remaining 
dendrimers. Solutions were sonicated, spun down, and finally analyzed for fluorescence 




and optimized to ensure that no significant amounts of dendrimer were used in the 
processing of the tissue (ref).  
Statistical Analysis 
Statistical significance was analyzed using student’s t-test assuming unequal variance. 
Values compared resulting in p-values ≤0.05 were considered significantly different.  
II.3 Results  
II.3.1 Dendrimer distribution on mouse colorectal tissue 
We have previously demonstrated the importance of sufficient PEG coverage of mucosal 
surfaces for efficient drug and gene delivery 261, 287, 289, and that hypotonic delivery can 
significantly enhance the distribution of non-mucoadhesive, but not of mucoadhesive, 
nanocarriers 61. Here, we first investigated whether PAMAM dendrimers are mucus-
penetrating in colorectal tissue, and what effect dendrimer surface functionality had on 
their distribution on the epithelial surface. When administered intrarectally, D-OH evenly 
coated the colorectal epithelial surface. We previously determined that non-mucoadhesive, 
or mucus-penetrating nanoparticles (MPP) evenly coat the colorectal epithelial surface and 
showed here that MPP distribute similarly to D-OH, indicating that D-OH also penetrate 
mouse colorectal mucus (Fig II-1) 7, 261, 287, 288. In contrast to D-OH, D-NH2 poorly 
distributed (<50% coverage) on colorectal tissue (Fig II-1), similar to mucoadhesive 
nanoparticles (MAP), indicating that D-NH2 may stick to mouse colorectal mucus 
7, 261, 287, 
288. D-COOH had intermediate distribution (50%-70% coverage) on the epithelial surface 
(Fig II-1). Based on these results, we determined that PAMAM dendrimer distribution 
increases in the following order: D-NH2<D-COOH<D-OH (Fig II-2A). Our studies also 




even distribution in Fig II-1; both D-NH2 and D-COOH aggregated in mucin bundles, 
similar to MAP (Fig II-2A, red arrows) 288. In contrast, D-OH penetrated through the 
mucus, reached the epithelial layer, and outlined the colonic crypts (honeycomb pattern) 
316, 317. Semi-quantitative assessment, using dendrimer fluorescence suggested that, D-NH2, 
D-COOH, and D-OH respectively coat <45%, 67 ± 5%, and >80% of the epithelial surface 
respectively (Fig II-2B).  
II.3.2 Cell uptake of dendrimers in colorectal epithelial tissue 
Researchers have shown that dendrimers are actively taken up by epithelial cells via 
clathrin and non-clathrin mediated internalization, depending on their surface functionality 
290-292, 306. We investigated whether surface functionality affects cellular uptake when 
dendrimers are exposed to epithelial surfaces in vivo. First, we used a method for tissue 
extraction that includes digesting the entire colorectal tissue, we found that D-OH had 
significantly improved cell uptake after 2 h, compared to D-NH2 (Fig II-3A). Due to the 
large errors of the complete tissue dissolution method (Fig II-3A), and the potential for 
dendrimer exocytosis from cells due to the lengthy incubation times (>24 h), we sought to 
test another method. We investigated a second method that only extracts the mucosal 
epithelium from the colorectal tissue, a method provides mostly epithelial cells for analysis 
315. Our data suggested that the PAMAM dendrimer surface functionality influences cell 
uptake, 30 minutes after topical administration to the colorectum. D-OH had significantly 
higher uptake than D-NH2, with >40% of cells showing presence of fluorescence from D-
OH, while <20% of cells showed presence of fluorescence after D-NH2 administration (Fig 
II-3B). D-COOH had intermediate cell uptake, ranging between D-NH2 and D-OH with 




distribution seen in Figure II-1, such that the amount of cells containing PAMAM 
dendrimer increased in the same order as the distribution: D-NH2<D-COOH<D-OH. Since 
the outer most layer of the colonic epithelium turns over rapidly 219, 220, we also investigated 
if D-OH remained in cells after several hours. When tissues were excised 4 h post 
administration, D-OH showed even higher uptake with >50% of cells showing 
fluorescence (Fig II-3B), indicating that D-OH may be able to penetrate past the outermost 
layer of colonic mucosal epithelial cells.  
II.3.3 Dendrimer retention in the colorectum 
In order to reach optimal therapeutic drugs levels, it is important to know the amount of 
drug carrier, and thus drug, present in the target tissue. Given that surface functionality of 
PAMAM dendrimers significantly affects their distribution as well as cellular uptake, we 
sought to determine the effects of dendrimer surface functionality on their retention in 
colorectal tissue. Interestingly, both D-OH and D-NH2 were retained at significantly higher 
levels than D-COOH (Fig II-4), despite our finding that D-NH2 reached less of the cells 
(Fig II-3). The amounts remaining in the tissue were 1.4 ± 0.9 µg/g, 1.7±0.6 µg/g, and 7 ± 
0.1 µg/g for D-OH, D-NH2, and D-COOH respectively (Fig II-4).  The differences between 
D-NH2 and D-OH were not significantly different due to variability between animals.   
II.3.4 Dendrimer distribution on various mucosal surfaces 
Having found that not all functional groups on dendrimers lead to even coating of the 
colorectal epithelial surface, we further investigated whether the distribution pattern of D-
NH2<D-COOH<D-OH translates to other mucosal surfaces such as the cervicovaginal tract 
and the lungs. In both the CV and respiratory tracts, D-OH completely coated the epithelial 




the vaginal epithelium after intravaginal instillation (Fig II-5). This result is similar to our 
results in the colorectum (Fig II-1). In case of the CV and respiratory tracts, D-OH 
distribution was also similar to that of MPP on these surfaces (Fig II-5) 261, 287, 289, indicating 
that D-OH can penetrate respiratory and CV mucus as well. In addition, in the CV tract, 
D-OH penetrated past the initial cell layers and got deeper into the CV epithelium (Fig II-
5, red arrows).  
In contrast to the evenly distributed D-OH, D-NH2 coated both the tracheal and the 
vaginal epithelium unevenly, and thus reached a smaller fraction of the epithelial surface 
(Fig II-5). Based on prior data, D-NH2 distribution is similar to mucoadhesive particle 
distribution in the CV and respiratory tract 7, 261, 287, suggesting that D-NH2 sticks to 
respiratory and CV mucus. Similar to our results in the colorectum, D-COOH distribution 
in the respiratory tract was intermediate between D-OH and D-NH2. Interestingly, D-
COOH distributed more evenly in the CV tract (Fig II-5), and coated a significant fraction 
of the epithelial surface (yellow arrows), but not as much as D-OH.  
II. 4 Discussion 
Our results indicate the interaction of water soluble PAMAM dendrimers with mucus is 
highly affected by their surface chemistry. In the colorectum, D-NH2 distribution is poor, 
while D-COOH distribution is intermediate, and D-OH distribution is the best, suggesting 
a hierarchy of distribution that follows D-NH2<D-COOH<D-OH. This relative distribution 
also correlates with the % cellular uptake of each of these dendrimers in the colorectum. 
Interestingly, the semi-quantitative assessment of cell uptake differed in that more D-NH2 
and D-OH were retained, compared to D-COOH. The high D-OH retention is likely due to 




dendrimer. On the other hand, the rapid and efficient uptake of D-NH2 into the cells they 
were able to reach likely caused the high D-NH2 retention. D-COOH had similar uptake 
efficiency to D-OH but poorer distribution on the epithelial surface 290-292, 304, 307, 318, 319. 
Our results indicate that D-OH may serve as superior nanocarriers for intracellular delivery 
to the mucosal epithelium, while D-NH2 and D-COOH are better suited for extracellular 
delivery.  
We have previously shown that surface distribution of nanocarriers can be 
indicative of their ability to penetrate through mucus 7, 287, 288. Nanocarriers that distribute 
poorly on mouse colorectal, vaginal, and tracheal tissues, such as hydrophobic polystyrene 
beads, were highly mucoadhesive, whereas non-mucoadhesive nanocarriers evenly coat 
the epithelial surface 261, 287, 289. The poor distribution of D-NH2 is indicative of its 
mucoadhesive properties. It is likely that the cationic surface causes D-NH2 to interact with 
the highly negatively-charged glycosylated regions on mucin strands (red arrows, Fig II-
2A), trapping D-NH2 that comes in contact with them. Prior work has indicated the 
negatively charged nanocarriers should penetrate mucus 156; however, our results suggest 
that D-COOH associated with mucins (red arrows, Fig II-2A), indicating that there is some 
interaction between mucus and D-COOH. This is somewhat in contrast to previous studies 
that have indicated that D-OH and D-NH2 interact similarly with ocular mucin, while D-
COOH interact significantly less 320. It is well-established that mucin composition differs 
at the various mucosal surfaces, likely altering the interaction with nanocarriers 8. In 
addition, experiments in those studies were performed with isolated mucin, where other 
components of mucus (such as lipids, proteins, or dead cell matter) that may alter the 




that is more representative of physiological conditions, indicating that in vivo D-OH are 
least affected by the mucus barrier. D-OH is thus a potential candidate for intracellular 
delivery to the mucosal epithelium.  
Epithelial uptake and paracellular transport of PAMAM dendrimers has been 
extensively studied in vitro and ex vivo. El Sayed et al studied the effects of dendrimer 
surface charge on cell layer permeability by assessing mannitol permeability. They found 
that D-OH cause nearly no increase in permeability 318, 319, while D-COOH and D-NH2 
significantly increased paracellular permeability. Hubbard et al showed that D-NH2 had 
greater tissue uptake and was poorly transported via the paracellular route, while D-COOH 
had increased paracellular transport but less tissue uptake 307. These previous studies help 
explain the difference in retention between D-COOH and D-NH2, as D-COOH would be 
translocated through the cells they reach while D-NH2 gets taken up. There are some 
significant limitations to using cell culture and ex vivo models, with respect to studying 
mucous transport. Most cell culture methods do not include the presence of mucus-
producing cells, leaving the epithelial cells completely unprotected and exposed to the 
dendrimers. In addition, many ex vivo models require the mucosal surface to be submerged 
in a significant amount of liquid, leading to dilution, excessive hydration, or removal of 
the mucus layer on the epithelial surfaces. Without a mucus layer, dendrimers can directly 
reach the epithelial layer and are more easily taken up by cells. Based on our current study, 
D-NH2 is trapped by the highly negatively charged mucin fibers in vivo within 5-10 
minutes. This is in contrast with previous studies that have indicated that uptake follows 
the order: D-COOH>D-NH2>D-OH 




in vivo cellular uptake follows the order D-OH>D-COOH>D-NH2, indicating that D-OH 
may be most suited for local drug delivery.  
Dendrimers have been studied for therapeutic and preventive applications in 
various mucosal surfaces. In fact, a class of polylysine dendrimer, Vivagel ®, is currently 
in clinical trials for the prevention of genital herpes virus infection 321. PAMAM 
dendrimers have also been shown to be effective for treatment of vaginal bacterial 
infections. Wang et al found that PAMAM dendrimers have significant antibacterial 
properties against E. Coli, leading to inhibition of bacterial infection of amniotic fluid when 
dendrimer was applied vaginally 322. In their studies, both neutrally charged D-OH and 
positively charged D-NH2 caused significant bacterial death, but cytotoxicity was 
associated with 100-fold lower concentrations of D-NH2 compared to D-OH, indicating 
the potential for use of D-OH in vaginal applications. Our studies further confirm that D-
OH may be more suitable for vaginal applications, as improved nanocarrier distribution 
has been shown to lead to better retention and efficacy in a mouse model of HSV 287.  
PAMAM dendrimers have also been used as drug carriers and absorption enhancers 
across the pulmonary epithelium 298, 323. Landers et al found that sialic acid conjugated to 
dendrimers successfully inhibits infection by influenza virus when delivered intranasally 
to mice 323. Inapagolla et al showed that FITC-labeled D-OH was retained in the lungs to a 
significant extent for up to six days298. In addition, these studies found that lower doses of 
methylprednisone (MP) are necessary for the same decrease in pulmonary inflammation 
when MP is conjugated to D-OH dendrimers compared to free drug 298. Suk et al have 
shown that non-mucoadhesive gene carriers that evenly coat the respiratory epithelium 




compared to free DNA 7. It is therefore not surprising that D-OH, which distribute similarly 
to non-mucoadhesive nanocarriers, are retained longer than free drug.  
Previous work has already indicated the benefits of dendrimers as drug carriers to 
the mucosal surfaces. Our results further elucidate the role of surface functionality and its 
effects on dendrimer-mediated drug delivery to mucosal surfaces. Based on our studies, D-
OH have the best distribution and % cellular uptake at various mucosal surface, and since 
D-OH have little cytotoxicity 302, 324, they have great potential for the treatment and 
prevention of diseases at mucosal sites in the CV tract, GI tract, and lungs. 
II.5 Conclusion 
We investigated the biodistribution of cationic (NH2), anionic (COOH), and neutral (OH), 
surface functional, generation-4 PAMAM dendrimers for potential drug delivery to various 
mucosal epithelial surfaces. Our results suggest that D-OH has significantly better 
distribution (>80% surface coating, and cellular uptake, >50% of extracted cells, on the 
colorectal epithelium) compared to D-NH2 (<45% of the surface, and <20% cell uptake). 
D-COOH has an intermediate distribution (~67 surface coverage, and 31% cell uptake). D-
NH2 and D-OH are retained in higher amounts than D-COOH in the colorectum after 2 h, 
likely due to rapid cell uptake of D-NH2 and a larger number of cells reached by D-OH. 
We also determined that D-OH evenly coats the epithelial surface of the lungs and CV 
tract, while D-COOH and D-NH2 do not. Our results indicate the suitability of D-OH 
dendrimers compared to D-COOH and D-NH2 as drug delivery vehicle to mucosal surfaces 






Figure II-1. Colonic distribution of PAMAM dendrimers after intrarectal 
administration to mice. Distribution in transverse colonic cryosections after hypotonic 
intrarectal administration of D-OH, D-COOH, and D-NH2 with 10x and 20x 



















































Figure II-2. Semi-quantified colonic distribution of PAMAM dendrimers after 
intrarectal administration to mice. (A) Distribution on flattened colonic tissue after 
intrarectal administration of D-OH, D-COOH, and D-NH2. Red arrows indicate 
dendrimers aggregated in mucus. (B) Semi-quantified surface coverage of D-OH, D-
COOH, and D-NH2 on flattened mouse colonic tissue. Images are representative of n ≥ 3 
mice and 6 images per tissue. White scale bar indicates 300 µm. Data are calculated as 
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Figure II-3. Quantified cell uptake of PAMAM dendrimers after intrarectal 
administration to mice. (A) Uptake of D-OH, D-COOH, and D-NH2 2 h after intrarectal 
administration to mice and extraction by tissue dissolution. (B) Uptake of PAMAM-OH, 
D-COOH, and D-NH2 30 min and 4 h after intrarectal administration to mice and 
extraction by removing only the mucosa. Data are calculated as means ± SEM. *P < 0.05 










































Figure II-4. Retention PAMAM dendrimers after intrarectal administration to 
mice. Data are representative of n≥3 mice and are calculated as average ± SEM. *P < 





Figure II-5. Distribution of PAMAM dendrimers after vaginal and intranasal 
administration to mice. Distribution in transverse cryosections of the vagina and trachea 
of mice after hypotonic intravaginal or intranasal administration of D-OH, D-COOH, and 
D-NH2. White scale bars represent 300 µm for vaginal sections and 100 µm for trachea 
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